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The Twin Arginine Translocase (Tat) is one of two protein translocation mechanisms 
in E. coli to move proteins across the inner bacterial membrane, from the cytosol to 
the periplasm. A unique feature of the Tat pathway is its ability to translocate fully 
folded proteins, indeed, in E. coli the Tat pathway preferentially transports correctly 
folded SURWHLQV7KLVµSURRIUHDGLQJ¶PHFKDQLVPDVLWKDVEHHQGXEEHGLVRILQWHUHVW
to the biopharmaceutical industry, however little is known of the mechanism by which 
Tat proofreads a substrates conformational state.  
Initial studies (chapter 3) addressed if the Tat proofreading mechanism sensed the 
surface charge or hydrophobicity of a substrate. To this end, surface residues of an 
scFv were mutated to create areas of charge and hydrophobicity without altering 
tertiary structure. Expression of these variants in E. coli revealed that Tat proofreading 
is tolerant of surface charge and hydrophobicity, but dependent on conformational 
flexibility. Further studies utilising a maquette in various folding states, confirmed Tat 
proofreading is sensitive to the structural rigidity of substrates (chapter 4).  
Investigations then went on to assess the quality of protein entering the periplasm via 
the Tat pathway by comparing it to the same protein transported by the General 
Secretory (Sec) pathway (chapter 5). This revealed, at least for a relatively simple 
biotheraputic, Tat-translocated protein is of the same quality to Sec-translocated 
protein.  
Finally, the question of what is responsible for the proofreading ability of Tat began 
to be addressed through C-terminal truncation studies of the Tat components that 
attempted to restore export of export-incompatible substrates (chapter 6).  
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Proteins, one of the essential constituents of life. They are large molecules or 
µmacromolecules¶ that carry out all manner of functions within an organism ± acting 
as signalling molecules, replicating DNA, catalysing reactions, facilitating cellular 
movement, and the transport of ions/molecules from one location to another, to name 
a few. However as beneficial as proteins are to an organism, if they are not at their 
correct site of function they can be incredibly damaging and failure is often a cause of 
disease. This poses a problem for most organisms as cells are composed of - and are 
often compartmentalised by - tightly sealed phospholipid membranes that very few 
molecules can cross without aid. The majority of proteins are synthesised in the 
cytoplasm and thus by necessity these barriers must be crossed (Wickner et al 1991).  
 
A variety of transport mechanisms have evolved to carry out the task of delivering 
substrates across lipid bilayers without compromising the structural integrity or 
function of the membrane. A variety of very different pathways have originated to 
facilitate the translocation of proteins, albeit in differing scenarios. Despite this 
diversity, translocation pathways have several key features in common ± a gated 
membrane-spanning pore (composed itself of proteins), an energy requirement to 
facilitate substrate translocation (usually in the form of hydrolysis of nucleoside 
triphosphates (XNTPs) and/or utilisation of the proton motive force SPIǻS+DQG
ǻȥ)) and in the case of protein translocation, delivery to the correct translocase via a 
specific (usually N-terminal) signal sequence.  
The focus here is on translocation of proteins across lipid bilayers in bacteria, for 




life (Natale et al 2008) - Eukarya, Archaea and Bacteria. This primary and 
predominant answer to the protein translocation conundrum is the General Secretory 
Pathway (Sec). In eukarya, the Sec pathway functions in the endoplasmic reticulum 
(ER) and serves to secrete proteins into the lumen of the ER where they are further 
delivered to their site of function (e.g. extracellular matrix (ECM)) by subsequent 
secretory steps (Golgi etc). Sec performs a similar function in bacteria and archaea, 
H[FHSWWKDWLW¶VORFDWHGLV the cell membrane. Plant plastids also utilise the Sec pathway 
to deliver proteins to the thylakoid lumen. Plastids (e.g. chloroplasts of plants or algae) 
and bacteria encode a second translocation pathway that also transports proteins to the 
thylakoid lumen and bacterial periplasm (Simone et al 2013). This second mechanism 
is the Twin Arginine Translocation (Tat) pathway. These translocation mechanisms 
are described in more detail in later sections and Figure 1 briefly outlines the site(s) of 
these translocating mechanisms.  
 
There are several properties shared by these translocation mechanisms which 
evidently form the basic necessities for a translocation system to correctly function. 
The first is a targeting mechanism to ensure substrates are directed to the appropriate 
transport pathway. This is in the form of an amino acid sequence, known as a signal 
peptide, usually located in the N-terminus of translating polypeptides. Second, is an 
environment to cross the membrane. This is in the form of a channel composed from 
membrane embedded proteins and associated soluble partners. Finally, some form of 







Figure 1: Overview and location of the General Secretory (Sec) and Twin-Arginine 
Translocase (Tat) pathways in bacteria, thylakoids and the eukaryotic ER. Although 
separate translocation mechanisms evolved, their components perform the same basic 
functions. Blue/Green/Yellow = General Secretory pathway. Orange/Pink/Red = Twin-
Arginine Translocase. 




























1.1 Targeting: the Signal Peptide 
 
Proteins destined for any of the membrane-crossing translocation pathways are usually 
translated as precursors that include a signal peptide to specify the translocase to be 
utilised. For the majority of translocase substrates, the signal peptide consists of the 
first 20 ± 50 residues, however for membrane proteins the signal peptide is usually the 
first TM domain (Blobel and Dobberstein 1975, Wickner et al 1991, Osborne et al 
2005, Natale et al 2008). Signal peptides are specific for the translocase they target to 
and, although they vary in individual amino acid composition from substrate to 
substrate, they have overall features. Sec and Tat signal peptides are tripartite 
consisting of a hydrophilic, basic N-domain, followed by a hydrophobic core region, 
known as the H-domain, and finally a polar C-domain (Berks et al 1996). Signal 
SHSWLGHVDUHFOHDYHGDIWHUPHPEUDQHWUDQVORFDWLRQDQGWKLVµFOHDYDJHVLWH¶resides in 
the C-domain consisting of short-chain residues at the -3 and -1 positions, usually Ala-
x-Ala (AxA).  
 
The structural criteria for a signal peptide appear to be conserved across organisms as 
thylakoid, bacterial and eukaryotic Sec and Tat signal peptides are similarly 
structured. Interestingly, Tat signal peptides function across organisms as thylakoid 
Tat signal peptides can target substrates to bacterial Tat machinery and vice versa 
(Mori and Cline 1998, Spence et al 2003, Aldridge et al 2008).  
 
Tat signal peptides differ from those that target substrates to Sec in several key areas. 
First, they are longer, at least 30 residues in length (compared to 17 ± 24 for Sec 
substrates), with additional residues predominantly located in the basic N-domain and 




increased length of the H-domain, Tat signal peptides are overall less hydrophobic 
than Sec, or even SRP, signal peptides (Cristóbal et al 1999). Second, Tat signal 
peptides contain the eponymous twin-DUJLQLQH PRWLI µ¶55¶¶ (Sargent et al 1998). 
These dual arginine residues reside within a larger S-R-R-x-F-L-K motif, found in 
nearly all Tat signal peptides spanning the junction of the N- and H-domains (Sargent 
et al 1998). Figure 2 gives a comparative overview of Sec and Tat signal peptides. 
While only the two arginine residues are invariant, the other residues are found with a 
frequency of > 50% (Berks 1996, Stanley et al 2000). While X can be any amino acid, 
it is usually polar. Numerous studies have shown the importance of the arginine pair 
for transport by the Tat system, both in bacteria and thylakoids. In bacterial and 
WK\ODNRLG7DWV\VWHPVVXEVWLWXWLRQRIµ55¶ZLWKGXDO/\VDFKDUJH-neutral change, 
RR > KK) blocks export completely, while in thylakoids RR > KR is tolerated, albeit 
with a decrease in export efficiency, and RR > RK abolishes export (Chaddock 1995, 
Halbig et al 1999). The situation in bacterial Tat is slightly different in that substitution 
of either arginine to lysine leads to a reduced level of export (Buchanan et al 2001). 
Some instances have been reported where a single arginine to glutamine substitution 
is tolerated (DeLisa et al 2002). These variations are only found experimentally and 
occur rarely in native Tat substrates with only one known protein reliably identified to 
cross the membrane via Tat harbouring a KR motif ± the TtrB subunit of tetrathionate 
reductase in Enterobacteriaceae (Hinsley et al 2001). Despite the abundance of work 
pertaining to the importance of the twin arginine residues, relatively little work has 
focused on the remainder of the residues in the Tat-targeting motif. However, one 
study indicated a residue of high hydrophobicity is important at the phenylalanine 





Figure 2: Tat and Sec signal peptides. Top: Comparison of Sec and Tat signal peptides, 
showing the basic N-domain (blue) followed by the hydrophobic H-domain (beige) and 
finally the polar C-domain (green) prior to the AlaXAla cleavage site. The Tat consensus 
motif, SRRxFLK, bridges the N- and H-domains. 
Bottom$FROOHFWLRQRI7DWVLJQDOSHSWLGHVZLWKWKHHSRQ\PRXVµ55¶PRWLILQEROGDQG















Apart from the twin-arginine motif, Sec and Tat signal peptides are highly similar and 
thus there must be more to the signal peptide that prevents targeting by the incorrect 
translocase. Several studies have suggested the C-domain contributes to avoidance of 
the incorrect pathway. In Tat signal peptides the region immediately prior to the AxA 
site is usually quite basic compared to the almost neutral charge of Sec signal peptides 
in this region ± around +0.5 and +0.03 (Berks, Palmer and Sargent 2003) respectively. 
This region of charge KDV EHHQ GXEEHG D SXWDWLYH µ6HF DYRLGDQFH¶ PRWLI ,QGHHG
adding positively charged residues in this region blocks Sec export. One study went 
IXUWKHU DQG VXJJHVWHG WKH µ6HF DYRLGDQFH¶ PRWLI HQFRPSDVVHV WKH AxA site and 
includes the first five amino acids of the mature protein (Bogsch et al 1997, Tullman-




In eukaryotes two proteins are predominantly associated with the luminal side of the 
translocation apparatus ± signal peptidase and oligosaccharyl transferase. These highly 
abundant proteins are often found in association with the Sec apparatus and serve to 
remove the signal peptide upon translocation of substrate (von Heijne 1998) and 
catalyse the addition of the oligosaccharyl moiety from dolichol to translocating 
polypeptides respectively.  
 
Signal peptidase generally cleaves at the AxA site and, while it performs a relatively 
simple function, is quite complex, at least in mammals and yeast. In mammals and 
yeast signal peptidase comprises 5 different membrane proteins ± SP18, SP21, SP22, 
SP23, SP25 and SP12. Each of these spans the membrane at least once while SP22/23 
is a glycoprotein (Paetzel et al 2002). The bacterial and thylakoid signal peptidase 
meanwhile is known as leader peptidase, or Lep1, and consists of only a single subunit 
that spans the membrane twice. Leader peptidase cleaves signal peptides from both 
Sec and Tat substrates once on the trans side of the membrane.  
 
 
1.2 General Secretory Pathway, Sec 
 
As early as the 1970s it was well understood that cells exported proteins from their 
site of synthesis ± the cytosol ± to the outer cell and the environment (Milstein et al 
1972). However, LWZDVQ¶WXQWLOWKHHDUO\µVWKDWJHQHWLFH[SHULPHQWV first identified 
the exact components that facilitate export across cell membranes to the periplasm in 
Escherichia coli and later in yeast. Two different but similar approaches identified the 
same three genes as being essential for viability. The first created mutations in signal 




that restored correct localisation. The resulting mutations were named prl genes for 
protein localisation (Bedoulle et al 1980, Emr et al 1981, Derman et al 1993). The 
second study screened for mutations that conferred conditional pleiotropic secretion 
defects, thus termed sec genes. The three genes identified in each study were SecY, 
SecE and SecA. Their individual roles in protein secretion were subsequently 
established by purification and reconstitution in vitro. These reconstitution assays 
helped to identify another component, SecG (Veenendaal and Driessen 2004). A third 
elegant assay utilised a chimeric protein made from the fusion of the N-terminal of 
maltose-binding protein (MBP), which is usually exported to the periplasm WR ȕ-
galactosidase (LacZ) which normally functions in the cytoplasm, to yield a different 
phenotype. This fusion WDUJHWV /DF= WR WKH LQQHU PHPEUDQH WKXV LQKLELWLQJ ȕ-
galactosidase activity (which usually occurs in the cytoplasm) and eventually stopping 
export machinery in wild-type cells. Thus proteins with mutations in secretion 
machinery have increased ȕ-galactosidase activity, due to accumulation of MBP-LacZ 
chimera in the cytoplasm, and a build-up of other secreted proteins (Ito et al 1981, 
Schatz and Beckwith 1990, Danese 1998). Several important proteins of the secretion 
machinery were identified in this manner.  
 
1.2.1 Components of the Sec machinery 
Translocation of proteins can occur at one of two stages ± during translation or after 
translation, termed co-translational translocation and post-translational translocation 
respectively. Transport across the phospholipid membrane at either of these stages 
utilises the same core components of the Sec machinery, composed from membrane 
proteins with associated soluble partners.  
The largest of these is Sec61ĮLQPDPPDOV which shares 56% amino acid homology 




al 1992). Eukaryotic Sec61 resides in the ER membrane whereas bacterial SecY is 
found in the cell membrane (Deshaies and Schekman 1987). This largest Sec 
component is 443 amino acids at 48 kDa (Cerretti et al 1983) and is composed of 10 
transmembrane (TM) helices in all cases, where both N- and C-termini are in the 
cytosol (Akiyama and Ito 1987). The Sec pathway only translocates proteins in an 
unfolded state and as such the pore only needs to accommodate substrates of a fixed 
diameter (that of a polypeptide chain) (van den Berg et al 2004). Various reports put 
the pore size in the region of 10Å ± 12Å as it can accommodate glass bearings of 10Å 
± 12Å and Į-helices with a diameter of 10Å (Mingarro et al 2000, Kowarik et al 2002) 
however, virtual simulations and the successful translocation of biotin-incorporated 
proteins allow the possibility that the channel is flexible and may be able to widen to 
16 ± 20Å (Kurzchalia et al 1988, Tani et al 1990, Tian and Andricioaei 2006).  
 
The primary component of the Sec machinery is SecY composed of 10 TM helices, 
these can be divided into two domains ± encompassing TM1-5 and TM6-10. These 
domains are pseudosymmetrical where TM6-10 are an upside-down version of TM1-
5 and are known as the C- and N-domains respectively (Akiyama and Ito 1987, van 
den Berg 2004, reviewed in Osborne et al 2005). Together these domains form an 
aqueous pore through which substrate polypeptides are translocated. 
 
The other core component of the Sec machinery needed for viability is the 127 amino 
acid, 14 kDa SecE (Schatz et al 1989). One of the methods used to affirm substrates 
are translocated via Sec is in SecE depletions strains where Sec secretion is non-
functional and in vitro reconstituted Sec translocases in proteoliposomes are functional 





N-in-C-out topology, whereas in Escherichia coli SecE folds into 3 TM helices with 
only the final helix sharing sequence similarity with the eukaryotic versions. Indeed, 
the 2 helices at the N-terminal of E. coli SecE are not essential for function (Murphy 
and Beckwith 1994).  
 
The third core component of bacterial Sec machinery is SecG which is smaller at 110 
amino acids and 12 kDa (Nishiyama et al 1993). Proteins that perform a similar 
IXQFWLRQFDQEHIRXQGLQPDPPDOVDQG\HDVW6HFȕDQG6EKSUHVSHFWLYHO\KRZHYHU
SecG shares no obvious similarity to these proteins. Although only SecY and SecE are 
HVVHQWLDO IRU YLDELOLW\ LQ WKH EDFWHULDO V\VWHP WKLV WKLUG µFRUH¶ FRPSRQHQW KDV D
stimulatory effect on translocation (Nishiyama et al 1993, Nishiyama et al 1994). 
SecG has N-in-C-in topology and forms 2 TM domains (Nishiyama et al 1996).  
 
Together SecY, SecE and SecG form a stable membrane embedded heterotrimeric 
complex named SecYEG, shown in Figure 3.  
 
The X-ray structure of Methanococcus jannaschii Sec<(ȕ has been solved to 3.2 Å 
resolution, and shows one copy of each subunit present and is analogous to E. coli 
SecYEG (van den Berg et al 2004). SecE and Secȕ6HF* are located on the periphery 
of the complex, with SecY in the centre forming a µ¶clamshell¶¶ shape laterally across 
the membrane (van den Berg et al 2004). The centre of the clamshell forms the channel 
through which polypeptides destined for the periplasm pass. This channel is thought 
WREHRSHQDWWKHF\WRSODVPLFIDFHDQGWKXVQHHGVDµSOXJ¶WRVWRSWKHXQZDQWHGOHDNDJH




segment, termed TM2a in the second transmembrane helix of SecY is thought to 
perform this role. This plug rotates back into a cavity on the periplasmic face during 
translocation, allowing access to the periplasm (van den Berg et al 2004, Flower 
2007).  
 
Although overall clamshell in shape, the channel formed by SecY is not strictly 
F\OLQGULFDODQGSRVVLEO\IRUPVDQKRXUJODVVVKDSHZLWKWZRLQYHUWHGµIXQQHOV¶PHHWLQJ
at a constriction point. These funnels are linHGZLWKK\GURSKLOLFUHVLGXHVWRµJXLGH¶
polypeptides through the membrane to the constriction point which is composed of 6 
hydrophobic residues (van den Berg et al 2004, Cannon et al 2005). In E. coli this pore 
ring is composed of Isoleucine residues and helps WR IRUP D µVHDO¶ DURXQG WKH
translocating polypeptide such that leakage of the membrane does not occur (van den 
Berg et al 2004). Polypeptides are then released into the periplasm via the second 
IXQQHOZLWKPRYHPHQWRI WKH70D µSOXJ¶ (Tam et al 2005). The loop connecting 
TM5 and TM6 forms the juncture of domains in SecY and this is thought to be the 
µKLQJH¶IRUWKHFODPVKHOOSecE VHUYHVDVDµEUDFH¶DURXQGWKLVKLQJHWKURXJKDQHWZRUN
of contact points. The arrangement of SecE, SecG and each of the SecY domains 
leaves the front of the clamshell able to open and this is likely how TM segments of 
membrane proteins laterally exit the SecY channel to enter the bilayer (van den Berg 
et al 2004). 
 
So far only the membrane components of Sec machinery have been described, the 
soluble components come in to play during translocation itself. As previously 
mentioned, membrane crossing via the Sec route takes place at one of two points ± co-




Figure 3: Eukaryotic and bacterial components of the General secretory (Sec) 
pathway. Also shown are co- and post-translational translocation (top two panels and 
bottom two panels respectively). In Co-translational translocation the bacterial Ffh (in 
mammals SRP) binds to the signal peptide of a newly translating polypeptide and guides 
the nascent-peptide-ULERVRPH FRPSOH[ WR )WV< 65Įȕ DW WKH PHPEUDQH EHIRUH
dissociating. This nascent-peptide-ribosome-SR complex is subsequently shuttled to the 
Sec translocation chaQQHO6HF<(*6HFĮȖȕZKHUHXSRQ65GLVVRFLDWHV7UDQVORFDWLRQ
DFURVVWKHPHPEUDQHWKURXJKWKH6HFFKDQQHOWKHQSURJUHVVHVXWLOLVLQJWKHµSXVKLQJ¶SRZHU
of GTP hydrolysis by the ribosome as the polypeptide elongates. Homologous subunits are 
coloured the same.  
The bottom panels show post-translational translocation, processes which differ 
significantly in eukaryotes and bacteria. The process is described in detail in the main text 





























1.2.2 Co-translational translocation 
All cells and organisms generally secrete proteins by co-translational translocation. 
However, the process is best described for eukaryotes. As a translated polypeptide 
emerges from the ribosome, information encoded in the signal peptide (section 1.1) 
triggers association with another soluble nucleoprotein complex. In eukaryotes this 
nucleoprotein is known as the Signal Recognition Particle (SRP). The eukaryotic SRP 
is a complex of a 300 nucleotide 7S RNA component intertwined with 6 polypeptides 
denoted 9, 14, 19, 54, 68 and 73, which corresponds to their molecular weights in kDa 
(Gundelfinger et al 1983). SRP binds to the signal peptide of the translating 
polypeptide via a methionine-rich domain (M-domain) in the 54 kDa polypeptide. 
Binding of SRP to the signal peptide pauses translation µHORQJDWLRQDUUHVW¶ and the 
close proximity of SRP to the ribosome increases affinity for GTP at the G-domain of 
the 54 kDa polypeptide (Freymann et al 1997, Zheng and Gierasch 1997). The 
ribosome-nascent chain: SRP complex now interacts with the SRP receptor (SR) on 
the membrane surface of the ER. SR is composed of two subunits ± a 30 kDa 
membrane-DQFKRUHG 65ȕ and a 70 kDa membrane-DVVRFLDWHG 65Į (Montoya et al 
1997). When GTP is bound to the G-GRPDLQ653LQWHUDFWVZLWK65Į (Legate et al 
2000). In eukaryotes interaction with the Sec61 channel is the only factor that leads to 
signal peptide release from SRP. Only after signal peptide release do SRP DQG65Į 
hydrolyse GTP causing dissolution of the RNC: SRP: SR complex, ready for new 
rounds of targeting (Miller et al 1993, Miller et al 1994, Powers and Walter 1995).  
 
The co-translational process is similar in bacteria, however the signal recognition 
particle is named Ffh (fifty-four homologue) and is much smaller at 48 kDa, composed 
of a shorter 114 nucleotide 4.5S RNA component and an SRP54-like polypeptide 




that the co-translational route is only used in bacteria for a portion of integral 
membrane proteins (Macfarlane and Muller 1995). Ffh binds the signal peptide as it 
emerges from the ribosome forming the RNC: Ffh complex whereupon it then 
associates with the membrane-DQFKRUHG )WV< D KRPRORJXH WR 65Į 7KHUH DV \HW
DSSHDUVWREHQR65ȕKRPRORJXHLQEDFWHULD (Ladefogen and Christiansen 1997). FtsY 
is located at the inner cell membrane of bacteria as there is no ER (Luirink et al 1994, 
de Leeuw et al 1997). Here it is the charge on the head groups of membrane 
phospholipids that promotes release of the signal peptide by Ffh (Luirink et al 1994). 
The scene from this point is very similar to that in eukaryotes ± FtsY guides the RNC 
complex to the core components of the Sec machinery, SecYEG.  
 
SR or FtsY directs the RNC complex to the Sec channel. According to the most recent 
single-particle EM, resolved to 17 Å, the eukaryotic ribosome-channel complex is 
FRPSRVHGRIIRXU6HFĮȖȕDVVHPEOLHVSHUWUDQVODWLQJULERVRPH (Manting et al 2000, 
Menetret et al 2000). The channel components are arranged as two side-by-side dimers 
which are themselves two back-to-back monomers. This arrangement is corroborated 
by the packing of 2D crystals for the E. coli SecYEG (Collinson et al 2001, Breyton 
et al 2002). Despite four Sec61 channels being present, only one is active and this sits 
within 12 Å ±  c RI WKH ULERVRPDO µH[LW¶ site, ready to receive the translated 
polypeptide (Mitra et al 2005)7KHUHPDLQGHURI6HFĮȖȕFRPSOH[HVSUHVHQWDUH
thought to aid recruitment of other soluble factors on both the cytosolic and luminal 
side of the membrane. For this quartet arrangement of Sec complexes, LWLVWKHȕ6HF*
subunit that forms the significant interface between complexes and this could be the 
reason for the stimulatory effect seen when SecG is added to in vitro reconstitution 




the ribosome that provides predoPLQDQWFRQWDFWVZLWKHDFKRIWKHIRXU6HFĮVXEXQLWV
DQGVHUYHV WR µDQFKRU¶ WKHULERVRPHDW WKHPHPEUDQH In this arrangement a newly 
translated polypeptide is passed directly from the ribosome into the membrane-
spanning channel and thus it is the hydrolysis of GTP by the ribosome that drives 
WUDQVORFDWLRQµSXVKLQJ¶SRO\SHSWLGHWKURXJKWKHFKDQQHO 
 
1.2.3 Post-translational translocation 
If a polypeptide is not translocated as it emerges from the ribosome, it crosses the 
requisite membrane after it has been fully synthesised ± post-translationally. 
Membrane crossing in this manner is the predominant route for bacterial polypeptides, 
although eukaryotic cells have a post-translational mechanism also. Unlike proteins 
that are translocated while being synthesised by the ribosome and thus utilise the 
energy derived from GTP hydrolysis to cross the membrane, proteins that cross post-
translationally via the Sec route get the necessary energy from ATP and PMF. In 
eukaryotes, such as yeast, several channel partners are required to facilitate post-
translational translocation. These are a tetramer composed of Sec62p/63p/71p and 72p 
that come together with the core Sec machinery to form a 7-component Sec complex. 
The situation is similar in mammals except there are no Sec71p/72p homologues. Once 
at the channel, polypeptides slide back and forth across the membrane due to Brownian 
motion. This alone would not achieve transport and therefore directionality is achieved 
through binding of a HSP70-like protein in the ER lumen termed BiP. BiP has an ATP-
binding domain and in the ATP-bound state, has an open peptide-binding pocket and 
readily binds incoming polypeptide from the Sec channel. BiP interacts with Sec63p 
at the J-domain, an interaction which increases the affinity of the peptide binding 
pocket for polypeptide and also stimulates ATP hydrolysis, causing the pocket to close 




incoming polypeptide and prevents backsliding. After sufficient forward movement of 
the polypeptide another ATP:BiP molecule binds to the polypeptide and the loss of 
contact of the ADP:BiP with the J-domain results in ADP-ATP exchange and opening 
of the peptide binGLQJSRFNHW,QWKLVPDQQHUWKHSRO\SHSWLGHLVJUDGXDOO\µ¶UDWFKHWHG¶¶
into the ER lumen (Matlack et al 1999, Haigh and Johnson 2002). It is important to 
note that BiP binding to polypeptide only occurs in the vicinity of the J-domain, 
therefore BiP does not interfere with downstream folding stages within the ER lumen.   
The post-translational scenario differs in bacteria in three key ways: first, bacteria 
employ a soluble partner in the cytosol, named SecA, that interacts with incoming 
polypeptide and utilises ATP and the PMF to move substrates through the SecYEG 
channel (Lill et al 1989). SecA is a large, 102 kDa protein of 901 amino acids and is 
composed of several domains, two of which are nucleotide binding domains (NBD), 
one with a high affinity for ATP (NBD1) the other with a lower affinity for ATP 
(NBD2) (Papanikolau et al 2007). 6HFRQGXQOLNHWKHµ¶UDWFKHW¶¶PHFKDQLVPRI%L3
6HF$DFWVDVDµSLVWRQ¶SXVKLQJSRO\SHSWLGHVDFURVVWKHPHPEUane. Finally, SecA is 
assisted by another soluble cytosolic protein, SecB (Driessen 2001).  
A polypeptide destined for the post-translational route emerges from the ribosome, the 
slightly higher hydrophobicity of its signal peptide decreases affinity for Ffh and 
increases affinity for SecB. Multiple copies of SecB bind pre-protein as it is translated 
to maintain it in a Sec-translocatable conformation i.e. unfolded (Kumamoto 1989).  
Under resting conditions, SecA exists in an equilibrium of two states ± the less 
abundant state is a soluble dimer in the cytosol and the larger portion as a monomer at 
the membrane, associated with the acidic phospholipid head groups and the SecYEG 
channel (Lill et al 1990). When not bound to SecB or pre-protein, SecA only 




increases the affinity of SecA for SecB: pre-protein complex (Hartl et al 1990). 
Binding of the pre-protein signal peptide to SecA increases SecA-SecB interaction and 
leads SecB to disengage from pre-protein. This greater interaction between SecA and 
SecB leads to exchange of ADP for ATP at NBD1, which in turn causes the release of 
SecB from the SecA: pre-protein complex and insertion of the 30 kDa domain of SecA 
into the SecY channel. Accompanied by the 30 kDa domain is 20 ± 30 amino acids of 
the pre-protein polypeptide. Hydrolysis of ATP at NBD1 promotes ATP hydrolysis at 
NBD2 which facilitates de-insertion of the 30 kDa domain from the SecY channel 
(Natale et al 2005). Pre-protein LVQRZLQWKHFKDQQHODQGFRXOGHDVLO\µEDFNVOLGH¶LQWR
the cytoplasm, however the PMF, although not essential for Sec-mediated protein 
translocation, is thought to stimulate translocation at this stage by decreasing 
backsliding (Schiebel et al 1991). In this manner, multiple rounds of SecB interaction, 
ADP: ATP exchange and pre-protein binding enable SecA to push pre-protein through 
the SecYEG channel across the membrane (Economou and Wickner 1994).   
 
In E. coli a second heterotrimeric complex interacts with the SecYEG channel during 
protein translocation and, while not essential in vitro (Matsuyama et al 1992, Duong 
and Wickner 1997), deletion mutants lack viability and protein export in vivo 
(Pogliano and Beckwith 1994). This second heterotrimeric complex is found as an 
operon on the E. coli genome and is composed of SecD, SecF and yajC. All three are 
integral membrane proteins of 67 kDa, 35 kDa and 12 kDa respectively. SecD and 
SecF are composed of 6-TM domains and a large periplasmic domain (the periplasmic 
domain accounting for 45 kDa in SecD and 11 kDa in SecF) whereas yajC has a single 
TM domain and a large cytosolic domain. Despite the importance of this 




1.2.4 Membrane insertion and YidC 
Co-translational translocation in bacteria is a route primarily reserved for integral 
membrane proteins (de Gier and Luirink 2003). During translocation, when a TM 
domain of pre-protein (which by default is largely hydrophobic) is spanning the SecY 
FKDQQHOWKHµFODPVKHOO¶WKDWLVWKHFKDQQHORSHQVDOORZLQJWKH70GRPDLQWRVOLGH
laterally into the membrane. A subset of E. coli integral membrane proteins require 
the aid of YidC. YidC is 62 kDa and is a homologue to the proteins Oxa1p and Alb3 
that perform similar functions in the mitochondrial inner membrane and thylakoid 
membrane respectively (Saaf et al 1998, van Bloois et al 2005). Like SecD and SecF, 
YidC has 6 TM domains and a large periplasmic domain and is thought to aid TM 
segments of translocating polypeptides slide out of the SecY channel into the 
membrane. Although only involved to varying degrees with a range of IMPs, YidC is 
essential for the insertion of the F0 domain of the E. coli F1F0 ATPase and cytochrome 
o oxidase of the electron transport machinery.  
 
 
1.3 The Twin Arginine Translocation pathway, Tat 
 
Some proteins are more complex, and thus require the insertion of cofactors (MGD, 
FeS etc) or oligomerisation before achieving functionality. In eukaryotes, secreted 
proteins are transferred as an unfolded polypeptide chain to the endoplasmic reticulum 
(ER) via the previously described Sec pathway (section 1.2). While in the ER these 
polypeptides fold into secondary and tertiary structures and are modified as necessary 
(e.g. glycosylation) to acquire their native state.  
Bacteria lack the compartmentalisation of eukaryotes and, while they do not encode 




oligomerisation. A sub-set of these reside in the periplasm, particularly those involved 
in, or related to, the respiratory pathway and electron transport chain.  
 
,Q WKH HDUO\ ¶V LW EHFDPH HYLGHQW WKDW WKHUH ZDV D VHFRQG VHFUHWRU\ SDWKZD\
functioning in bacteria and thylakoids, working in parallel to the Sec pathway. This 
was first identified transporting proteins into the thylakoid lumen of plant chloroplasts. 
Soon after, homologues were identified in bacteria that facilitated protein transport 
across the cell membrane to reach the periplasm. Interests piqued in this newly 
discovered pathway when it was shown to enable membrane crossing for several 
heterologous proteins the Sec system could not handle. The first of these was 
dihydrofolate reductase (DHFR) bound to methotrexate (Hynds et al 1998), a complex 
known to be incredibly tightly folded. Secondly, GFP was able to be exported to the 
periplasm of bacteria in fluorescent state when fused to a Tat-specific signal peptide 
(Santini et al 2001, Thomas et al 2001), a feat not possible when GFP folds in the 
periplasm after translocation via the Sec pathway. Thirdly, instances of membrane 
crossing for protein complexes were reported (Rodrigue et al 1999, Wu et al 2000), 
indicating the Tat system could transport large, folded substrates. Further studies 
confirmed this pathway did indeed facilitate folded protein transport across the lipid 
ELOD\HU,QLWLDOO\QDPHGWKHǻS+-pathway in thylakoids due to the sole requirement of 
a proton gradient for translocation (Mould et al 1991 and Yahr et al 2001) and Mtt 
(membrane targeting and translocation (Weiner et al 1998)) in bacteria, it has since 
been re-named and will be referred to from here on as the Twin Arginine Translocase 





1.3.1 Components of the Tat pathway 
The first identified component of the Tat machinery was Hcf106, found in the 
thylakoids of maize plant chloroplasts (meaning High chlorophyll fluorescence 106) 
(Settles et al 1997). This was closely followed by the discovery of the remaining 
components of the Tat machinery ± Tha4 and cpTatC (Mori and Cline 2002). 
Homologues to these three proteins were quickly identified in bacteria. 
Minimally the Tat machinery is composed of only two classes of proteins ± TatA-like 
and TatC-like, however this varies greatly from organism to organism and more 
commonly the Tat system is composed of two TatA-like proteins that perform distinct 
functions, and a single TatC-like protein (Goosens et al 2013).  
 
Such a trimeric Tat system is found in Escherichia coli with the TatA-like components 
named TatA and TatB while the TatC-like protein is simply named TatC (homologous 
to chloroplast Tha4, Hcf106 and cpTatC respectively). TatAB and TatC are encoded 
as a tatABCD operon located at min 86 (Figure 4) with another gene, tatE, located 
elsewhere in the genome. All are constitutively expressed, although to varying levels, 
with TatA found at 50- and 25-fold abundance relative to the core Tat components 
TatC and TatB (Jack et al 2001). Expression levels are reflected in component make-
up of the final translocase (section 1.3.3). Although ǻWDW$%&'( strains are still viable 
they exhibit reduced vitality as the bacterial Tat system is important for energy 
metabolism, formation of the cell envelope, biofilm formation, heavy metal resistance, 
nitrogen-fixing symbiosis and bacterial pathogenesis (Berks et al 1996, Oschner et al 







Figure 4:  Schematic of Escherchia coli Tat components and complexes. TatAB and 
TatC are encoded in the tatABCD operon located at min 86 on the E. coli genome, while 
tatE is encoded at min 14 (top). Individual component size and orientation in the membrane 
are shown in the middle panel. Generally accepted complexes are shown in the bottom 



















TatA is an 89 amino acid, 9.6 N'DSURWHLQZLWKSUHGRPLQDQWO\Į-helical secondary 
structure (Weiner et al 1998). It consists of a small, unfolded N-terminal domain 
exposed to the periplasm (Walther et al 2010, Koch et al 2012), followed by a 
transmembrane (TM) helix and an amphipathic helix (APH) ending in a C-terminal 
domain of ~40 residues that form an unstructured tail (Hu et al 2010, Rodriguez et al 
2013). Solid-state NMR indicates the TM helix spans the membrane at a 17° tilt 
(Müller et al 2007, Walther et al 2010), while CD and oriented CD spectroscopy 




and APH are connected by Glycine 21 (in E. coli) which is central to the µ¶KLQJH¶¶
region composed of the FGx motif (Barrett et al 2003) that also maintains the relative 
angle of the helices through packing interactions, known as the µ¶KLQJH-EUDFH¶¶. The 
glycine at this position is one of the only residues conserved throughout TatA-like 
proteins and is essential for function. The amount of movement around this hinge 
region is under discussion, however it potentially plays a role in the translocation 
mechanism (section 1.3.4). The APH is hydrophobic facing the membrane and 
displays a charged face towards the cytoplasm. A recent solution NMR study of TatA 
has shown the APH to be anchored in the membrane by Phenylalanine 39, with 
substitution of this residue to alanine inactivating the translocase (Hicks et al 2003, 
Rodriguez et al 2013). TatA is thought to be the subunit responsible for forming the 
pore in the activated translocase.  Cysteine scanning mutagenesis studies on TatA 
reveal that individual amino acids in the APH are critical to function, with single 
substitutions in this region commonly abolishing a functional translocase, whereas the 
only residue identified to be important in the TM domain is Gln8 (Greene et al 2007). 
A similar result was obtained in an elegant loss-of-function assay (Hicks et al 2005). 
This is in marked contrast to TatB in which the only essential specific amino acids 
appear to be those in the short N-terminal domain.  
 
1.3.1.2 TatB 
The second TatA-like protein in E. coli is TatB, a 171 amino acid, 18.5 kDa protein 
that despite sharing only 20% sequence identity with TatA, is predicted to fold to a 
highly similar structure (Hicks et al 2003). TatB possesses a short N-terminal region 
exposed to the periplasm, followed by a TM helix and the conserved glycine 21 residue 
LQWKHµKLQJH¶UHJLRQ this time in a xGP motif (Barrett et al 2003). Interestingly plant 




(Barrett et al $IWHUWKHµ¶KLQJH-EUDFH¶¶UHJLRQ TatB begins to differ from TatA. 
The amphipathic helix is likely longer than that in TatA, extending by 12 amino acids 
(corresponding to ~ 3 extra turns of the helix) and the unstructured C-terminal domain 
is considerably longer (Zhang et al 2014). TatB also lacks the phenylalanine residue 
in the APH that is conserved in TatA (Phe39). Unlike TatA, TatB is not involved in 
the translocating pore, but plays an important role in the substrate-docking complex 
and thus despite having likely arisen from a gene duplication event (Yen et al 2002), 
TatA and TatB have diverged to perform different, but essential, functions (Sargent et 
al 1999). Interestingly, despite the relatively low level of sequence similarity between 
TatA and TatB it has been shown that only a few, minor mutations are needed in TatA 
such that it can complement ǻWDW% strains (Blaudeek et al 2005). Complementary to 
this a chimeric TatA/B protein composed of the N-terminal TM domain of TatA fused 
with the APH and C-domain of TatB was able to support low levels of Tat activity in 
either ǻWDW$(or ǻWDW% strains.  
 
1.3.1.3 TatC 
The final core component of the E. coli Tat system is TatC. A considerably larger 
protein, TatC is 28.9 kDa formed of 258 amino acids that fold into six TM helices with 
both N- and C-termini in the cytoplasm (Behrendt et al 2004, Punginelli et al 2007). 
As well as being the largest of the Tat components, TatC has the most highly 
conserved amino acid sequence of all subunits across both bacteria and plants, with 
the majority of conserved residues residing in the cytoplasmic loops (Kneuper et al 
2012, Ma and Cline 2013). The conserved nature of TatC is likely due to the central 
role it plays in recruitment of other Tat subunits and substrate binding and recognition. 
The recent crystallisation of Aquifex aeolicus TatC (which shares 40% sequence 




and 6.8 Å), each identified the same structure for TatC indicating it has limited 
conformational states (Rollauer et al 2012). The six transmembrane domains of TatC 
IRUPDFRQFDYHµERZO¶VWUXFWXUHIDcing the periplasm due to the shorter nature of TM5 
and TM6 (Ramasamy et al 2013). These shorter helices contribute to the overall 
concave shape of TatC while also forming a cavity capped by a periplasmic loop and 
distort the membrane in their vicinity. This distortion of the membrane likely causes 
membrane thinning around the periphery of TatC and could be involved with the 
membrane-crossing event of Tat-targeted substrates.  This cavity also harbours a 
glutamate residue (Glu165 in A. aeolicus) which, rather interestingly is conserved as 
a glutamate or glutamine in TatC components of all organisms (Buchanan et al 2002). 
Molecular dynamics simulations indicate this polar residue is hydrated and at least 
occasionally exposed to the cytoplasm thus could potentially play a role in signal 
peptide binding to TatC (Ramasamy et al 2013).  
 
1.3.1.4 TatE 
In E. coli the core subunits of the Tat machinery are TatABC, however in this organism 
there is also another TatA-like protein, TatE, located at min 14 on the genome. TatE 
is highly similar to TatA at 67 amino acids of which 57% are identical to that of TatA 
(Sargent et al 1998) and likely arose from a gene duplication event (Yen et al 2002). 
As with the TatABC components, TatE is expressed constitutively although to much 
lower levels, 50- to 100-fold less than TatA (Jack et al 2001). When overexpressed 
form an exogenous plasmid, TatE can functionally replace TatA (Sargent et al 1999), 
restoring export in ǻWDW$ strains, however its function under physiological conditions 
is as yet unknown although recent evidence suggests it is a regular, albeit scarce, 





The final protein expressed from the tatABCD operon is TatD. Unlike the other Tat 
components, TatABCE, which are integral membrane proteins, TatD is a soluble 
cytoplasmic protein of 28.9 kDa. It has been shown to have no impact on Tat 
functionality and, due to the 33% sequence similarity to the Chlamydophila 
pneumoniae protein YabD and activity in the presence of Mg2+ is likely a magnesium-
dependent DNase. It has thus been proposed that the only reason tatD resides in the 
Tat operon of E. coli is that it has similar transcriptional requirements.  
 
1.3.2 Tat systems in other organisms 
Nearly all bacteria, archaea and chloroplasts encode Tat systems, it is merely the 
number and variety of substituent components that differ. Utilisation differs from 
organism to organism with Gram-positive bacteria (e. g. Staphylococcus aureus and 
Bacillus subtilis) having few identified Tat substrates (Dilks et al 2003, Tjalsma et al 
2004) whereas the enteric bacterium E. coli encodes 20 ± 30 Tat substrates (Palmer, 
Sargent and Berks 2010). This variety is reflected in the encoded Tat systems, for 
example B. subtilis encodes two distinct Tat systems, both of which are minimal in 
that they are composed of only a single TatA-like and single TatC-like protein 
(Jongbloed et al 2004). These are TatAdCd encoded by the phoD operon which has a 
single substrate, PhoD, and is expressed under phosphate-limiting conditions and 
TatAyCy ± a constitutively expressed Tat system with under 10 substrates. These Tat 
systems are variably expressed in parallel and are still able to maintain function. B. 
subtilis also encodes a third TatA-like protein, TatAc, the function of which is largely 
unknown, although it possibly plays a small role in both TatAdCd and TatAyCy 
systems. Indeed many gram-positive bacteria utilise Tat systems composed of a single 




three of the identified TatA-like proteins to date ± that of B. subtilis TatAd (Hu et al 
2010) and the E. coli TatA and TatB (Rodriguez et al 2013, Zhang et al 2014a, Zhang 
et al 2014b). Rather unsurprisingly there is little difference between them. Moreover 
the TatA component (e.g. TatAd) is bifunctional in that it is able to complement either 
tatA or tatB null E. coli strains (Barnett et al 2008).     
 
1.3.3 Structure of the TatABC complex 
Unlike the Sec system, which transports pre-proteins in an unfolded state and thus 
only has to accommodate substrates of a single, small, defined size, the Tat system 
transports folded substrates. Folded substrates are by definition globular and of various 
shapes ± ranging from 25 ± 70 Å diameter (Berks et al 2000) ± and sizes ± 
encompassing small, 10 kDa high-potential iron-sulphur proteins to the large, 150 kDa 
formate dehydrogenase in E. coli (Brüser et al 2003, Jack et al 2004). Therefore, given 
the relatively small size of the individual Tat components a translocase must coalesce 
from multiple copies of each of the individual subunits.  
Two such complexes have been identified to date ± the first of these is composed 
essentially of TatB and TaC with trace amounts of TatA in E. coli and is known as the 
substrate receptor complex (Bolhuis et al 2001). These TatBC complexes are so named 
as there is significant evidence to show that this is where Tat-specific signal peptides 
bind (Lausberg et al 2012). Sequence conservation, site-specific cross-linking and 
genetic studies agree that the charged N-region of the Tat signal peptide (section 1.1) 
first binds to a surface patch on TatC formed by the N-terminal of TM1 and the 
cytoplasmic loop between TM2 and TM3 (Gerard et al 2006, Kreutzenbeck et al 2007, 
Rollauer et al 2012, Zoufaly et al 2012, Ma et al 2013) where WKHFRQVHUYHGµ55¶LQ
the signal peptide possibly interacts ZLWKFRQVHUYHGµ((¶UHVLGXHVLQ WKH7DW&ORRS 




the interior of TatC, reaching the cavity formed by TM5 and TM6, where the C-
domain of the signal peptide possibly reaches the periplasm at the periplasmic cap, 
exposing the cleavage site to signal peptidase (Berks, Lea and Stansfeld 2014). 
Similarly, cross-linking studies and modelling between TatC and TatB place the TM 
domain of TatB within, or near the cavity formed by TM5 and TM6 of TatC (Kneuper 
et al 2012, Rollauer et al 2012, Blummel et al 2014). Cross-links between the H-
domain of signal peptide and TatB TM domain have also been observed (Aldridge et 
al 2014) and indicate TatB also plays a role in signal peptide binding (Maurer et al 
2010).  
 
It is well established that the substrate binding complex is composed of equimolar 
amounts of TatB and TatC (Bolhuis et al 2001), which in E. coli purify as complexes 
of 370 kDa, as determined by blue-native polyacrylamide gel electrophoresis (BN-
PAGE) (Bolhuis et al 2001). Thus corresponding to ~ 7 copies of each subunit (Tarry 
et al 2009, Celedon et al 2012) and electron microscopy of TatBC reveals a 
hemispherical complex of 11 ± 17 nm in diameter (Tarry et al 2009), large enough to 
account for an equivalent number of each subunit but not large enough to 
accommodate native Tat substrates and thus be the pore. The multiple copies of TatBC 
in these complexes would imply there are sites for multiple substrates to bind (Celedon 
et al 2012). It is unclear whether substrate binding to these sites are cooperative or not 
(Alder and Theg 2003a, Celedon et al 2012), however it is generally accepted that 
while the signal peptide enters deep within individual TatC units (Gerard et al 2007), 
the bulk of the substrate remains at the periphery of TatBC (Ma and Cline 2010, Tarry 
et al 2009). While TatA is not obligatory for the formation of TatBC complexed or 




associated with TatBC within the membrane and these are thought to be nucleation 
points for larger TatA oligomers to form to facilitate the membrane-crossing event 
(Aldridge et al 2014).   
 
The second complex is highly heterogeneous in size and is composed predominantly 
of TatA with trace amounts of TatB. Interestingly these TatA oligomers are found in 
both the membrane and soluble in the cytosol (Keersmaeker et al 2005, Westermann 
et al 2006, Frielingsdorf et al 2008). Although the function of the membrane-
embedded complexes is likely involved in the membrane-crossing event, the purpose 
of soluble TatA-like proteins remains unclear. These TatA oligomers appear as 
FKDUDFWHULVWLFµODGGHUV¶RQ%1-PAGE ranging in size from 100 kDa to 500 kDa (Oates 
et al 2005). TatA oligomers of this size only form once substrate has bound to TatBC 
in the presence of a PMF. While under non-translocating conditions TatA is thought 
to form tetrameric protomers (Leake et al 2008, Dabney-Smith and Cline 2009). 
Various studies have attempted to view these structures and identify their protein-
protein interactions, as these would be important to elucidating the translocation 
mechanism, as 7DW$ROLJRPHUVDUHWKRXJKWWRIRUPWKHWUDQVORFDWLRQµSRUH¶+RZHYHU 
it is difficult to isolate the active translocon due to their transient nature ± TatA 
oligomers disperse upon successful translocation (Mori et al 2002). However, a recent 
study used site-directed, photo-activated cross-links to link a substrate to both TatA 
and TatB subunits, implying these both play a role in the translocation pore. Cross-
links to TatB in this scenario could also be explained by the proximity of TatA and 
TatB binding sites on TatC. Current structural data on TatA-like oligomers are derived 
from TatAd purified from its native environment (the cell membrane) and solubilised 




solubilised TatAd complexes reveals ring-like structures of various sizes, matching 
the data of BN-PAGE. The larger of these ring-structures have internal cavities that 
are large enough to accommodate folded substrate proteins. One study controlled TatA 
oligomer size by altering the protein to detergent ratio in an effort to identify protein-
protein contacts. Solution NMR of the smaller of these oligomers indicated TatA 
monomers interact through their TM domains while the APH µsplay¶ out from a central 
70GRPDLQµFRUH¶. Modelling showed this was a feasible scenario for up to 25 TatA 
subunits, at which point steric hindrance of residues in the APH limited further TatA 
monomer addition (Rodriguez et al 2013). These data match that garnered from spin-
labelling (White et al 2010) and disulphide-bonded dimer experiments (Zhang et al 
2014). These structures would be unstable however and require stabilising interaction 
with TatC. Cross-linking studies have placed TatA-TatC interactions between the 
TatA TM domain and the TM5 cavity of TatC (Berks 2015).   
 
1.3.4 Mechanism of translocation 
Translocation of proteins across the inner membrane of bacteria and thylakoid 
membrane initiates upon binding of substrate signal peptide to the TatBC or Hcf106-
cpTatC respectively, substrate receptor complex (Alami et al 2003). Once docked at 
the membrane, TatA (or Tha4 in thylakoids) SURWRPHUV DUH UHFUXLWHG LQ D ǻS+-
dependent manner (Cline et al 2001, Mori et al 2002) to form the functional TatABC 
translocase.  
The transient nature of the active translocase KDVSURYHQGLIILFXOWWRµFDSWXUH¶LQWKH
process of facilitating membrane crossing of a substrate. Given the heterogeneity of 
Tat substrates in size and shape it is difficult to conceive of a membrane-spanning 
channel, such as represented by the SecY protein. Such a channel would have to be 




and would prove difficult to inhibit the unwanted passage of ions and molecules across 
the membrane. Regardless, the initial stage of any translocation model for the Tat 
apparatus is guidance of substrate to the TatBC receptor complex and binding of the 
Tat-specific RR signal peptide at this site, a process likely driven by TatC (Frobel et 
al 2012). Following substrate docking the exact mechanism of membrane crossing 
becomes unclear; however, due to the experimental data available two possible 
mechanisms of protein translocation have been put forward.  
 
7KHILUVWLVWKHµ7UDQVORFDWLRQSRUH¶PRGHOFUHDWHGDQGRULJLQDOO\IDYRXUHGGXHWRWKH
flexibility implied by the conserved glycine µKLQJH¶UHJLRQLQWKH7DW$VXEXQLW (Gouffi 
et al 2004) and single particle electron microscopy data which identified TatA pore-
like structures of various sizes (Gohlke et al 2005, Oates et al 2005). In this scenario, 
once substrate is docked at TatBC, TatA protomers are recruited to suite the size of 
WKHVXEVWUDWHSURWHLQZLWKWKH70KHOL[IRUPLQJWKHµZDOOV¶RIWKHpore and the APH 
IRUPLQJDµJDWH¶DWWKHF\WRSODVPLFIDFHRIWKHPHPEUDQH (Gohlke et al 2005, Walther 
et al 2013). Recruitment of protomers is supported by the homogeneity of TatE and 
TatAd complexes identified in E. coli and B. subtilis respectively, which, unlike TatA 
oligomers that range in size, are usually restricted to ring structures of a single size at 
~160 kDa and a diameter of 6 nm ± 9 nm, far too small to accommodate the larger Tat 
substrates (Baglieri et al 2012, Beck et al 2013). 
 
6XEVWUDWHZRXOGWKHQSXVKWKURXJKWKLVµJDWH¶ZLWKWKH$3+KLQJLQJLQWRWKHFKDQQHO
such that the hydrophobic face aligned with complementary charges on the TM helix. 
The charged face would then line the channel, providing a suitably hydrophilic 




again lie parallel to the membrane at the cytosolic face, closing the channel and 
limiting passage of ions. Finally, the TatA pore dissociates. Recent evidence has cast 
doubt on this model however as the APH is not accessible from the periplasm (Koch 
et al 2012, Aldridge et al 2012) DQGWKHµKLQJH¶UHJLRQpossibly lacks enough flexibility 
to allow this hairpin arrangement (Walther et al 2010). Solution NMR of TatA 
ROLJRPHUV DOVR LQGLFDWHV WKDW WKH$3+IDQRXWZDUG IURPDFHQWUDO70KHOL[ µFRUH¶ 
(Rodriguez et al 2013).  
 
The second possibility and interesting alternative to the translocation pore model, is 
WKDWWKH7DWWUDQVSRUWPHFKDQLVPZRUNVE\µ0HPEUDQHGHVWDELOLVDWLRQ¶ (Brüser and 
Sanders 2003). This model focuses on the unconventional idea that the Tat 
components inherently destabilise the membrane in their vicinity. Membrane 
destabilisation in this manner arises from two areas ± a possible disruption of 
phospholipid head groups by the proximity and angle of the APH (Brüser and Sanders 
2003, Greene et al 2007) and the mismatch between the length of the TatA TM helix 
and the width of the bilayer (the TM helix is slightly shorter than the bilayer width) 
(Rollauer et al 2012, Rodriguez et al 2013). This latter disruption could be enhanced 
by the disruption caused by TM5 and TM6 of TatC. Molecular dynamics simulations 
have shown that disruption of the membrane due to these effects could thin the bilayer 
by 80% with the phospholipids in the vicinity highly disordered (Rodriguez et al 
2013). Substrate movement through this weakened and thinned bilayer would be far 
easier, especially if mechanical force is applied, whilst also maintaining the ionically-
sealed nature of the membrane (Berks 2015). During membrane crossing fewer ions 





Figure 5: Proposed translocation mechanism for the Tat pathway. While the exact 
mechanism of translocation is unknown, the initial stage in any Tat translocation model is 
targeting and binding of substrate to the TatBC substrate receptor complex by the N-
terminal signal peptide. At this point, translocation becomes less defined, however two 
scenarios have been envisioned. 1) Translocation pore model: TatA protomers create a 
channel to fit the size of the substrate with the TatA TM helix lining the channel while the 
$3+IRUPDµ¶JDWH¶¶0HPEUDQHGHVWDELOLVDWLRQPRGHO: The short nature of TatA TM 
helix causes deformation and thinning of the membrane in the local vicinity of TatA by up 
WRDOORZLQJVXEVWUDWH WRµVOLS¶DFURVV ,QHLWKHUPRGHORQFH7DW$SURWRPHUVKDYH
coalesced, substrate proceeds to traverse the membrane before the signal peptide is 
removed by leader peptidase and substrate released into the periplasm. 
the SecY channel. Several studies have implicated the TatBC substrate-binding 
complex, specifically TatC in providing the mechanical energy for such a mechanism, 
SRVVLEO\E\XWLOLVLQJWKH30)WRµSXOO¶RQWKHERXQGVLJQDOSHSWLGH (Lindenstraub et al 
2009, Taubert et al 2014). These mechanisms are summarised in Figure 5.  
Despite the abundance of data available, due to the lack of- and inherent difficulty in- 
isolating an active Tat translocon, understanding the exact mechanism of Tat transport 









1.3.5 Energy requirement of the Tat system 
The current understanding for translocation by the Tat system indicates it is powered 
solely by the PMF (ǻS+). This is an unusual feature for protein translocation 
machinery, which are usually powered by hydrolysis of nucleoside triphosphates 
(ATP or GTP). 
 
Early research into the energetics of the Tat pathway were carried out in the plant 
thylakoid system. This was due to the ease of preparing chloroplasts for both in vivo 
and in vitro studies FRPELQHGZLWKWKHDELOLW\WRFRQWUROWKHSUHVHQFHRIDǻS+E\WKH 
presence or absence of light (Mould and Robinson 1991, Mori and Cline 2002).  These 
found that import of the 23K protein of the oxygen evolving complex into thylakoids 
was only accomplished in the presence of light DQGDǻS+DQGVWLOORFFXUUHGLQWKH
absence of nucleotides (Mould and Robinson 1991, Mori and Cline 2002). Due to a 
decrease in rate of import in D2O it was thus proposed that translocation of proteins 
across the membrane was coupled to the transfer of protons in the opposite direction, 
in an antiporter mechanism (Musser and Theg 2000). The average amount of 
counterflow of protons necessary for a protein to cross the membrane by the 
chloroplast pathway was calculated to be in the region of 7.9 x 104 protons per 
molecule. This corresponds to the energy contained in 10 000 ATP molecules, 3% of 
the energy produced by chloroplasts, a considerable cost to the cell (Alder and Theg 
2003b). 
 
$ VLPLODU GHSHQGHQFH VROHO\ RQ WKH ǻS+ ZDV REVHUYHG IRU WKH 7DW$%& system of 





1.3.6 Proofreading and Quality control 
Proteins identified as being routed via the Tat machinery to cross the inner membrane 
generally fit into three categories: 1) proteins binding complex cofactors that require 
enzymatic insertion, a process more suited to the protected environment of the 
cytoplasm and avoids exporting multiple chaperone proteins as well as the cofactor(s), 
which may require an extra transport mechanism of their own. 2) Proteins allowing 
sites potentially sensitive to external metal ions (such as the active site), to be 
sequestered or bind a suitable ligand first. 3) Proteins forming into hetero-oligomeric 
complexes that would otherwise not assemble in the periplasm (Patel, Smith and 
Robinson 2014). All of the three categories undertake processes that are complex and 
could easily go awry, resulting in malfunctioning protein being produced ± a 
disastrous result for the cell. The majority of Tat substrates identified to date are 
cofactor-binding proteins, where the most abundant cofactors are Fe-S, molybdopterin 
and Ni-FeS centres, with a few examples of oligomeric complexes. However, a few 
substrates fit none of these categories and thus likely fold too rapidly to be reliably 
exported via Sec (e.g. AmiA, AmiB and AmiC).  
 
There is widespread evidence indicating the Tat system has a proofreading and quality 
control mechanism to ensure such malfunctioning substrates do not cross the bilayer 
and are instead degraded (Halbig et al 1999, DeLisa et al 2003, Matos et al 2008).  
 
It is apparent that native Tat substrates undergo stringent quality control prior to even 
reaching the Tat apparatus, particularly oxidoreductases for example trimethylamine-
N-oxide (TMAO) reductase and dimethylsulfoxide (DMSO) reductase. These Tat 
substrates are encoded in an operon with subunit partners and also additional proteins 




features and are involved in the biogenesis of cognate cofactors and maturation of the 
final Tat substrate, thus they have been dubbed redox enzyme maturation proteins, 
REMPs. 
 
REMPs perform many functions in oxidoreductase maturation including: protease 
protection of newly synthesised proteins, RR signal peptide interaction, maintaining 
the oxidoreductase in a cofactor-competent state, membrane interaction and targeting 
to the Tat apparatus. Tight binding of REMPs to their cognate protein is usually in the 
C-domain of the Tat signal peptide. This would serve to block the AxA motif to retain 
targeting by the signal peptide whilst retarding the journey to the translocase, allowing 
the pre-protein time to suitably fold and acquire necessary cofactors before docking at 
TatBC. For example, in the torCAD operon torA encodes TMAO reductase and torC 
encodes a haem-binding quinol oxidase, meanwhile torD is the REMP associated with 
TMAO. TorD has been shown to bind to apo-pre-TMAO in the cytoplasm at two sites 
± the C-domain of the signal peptide and with lower affinity to a sequence of the 
mature protein that is only in close enough proximity to the signal peptide in the folded 
state.  In this manner TorD systematically aids protein folding and cofactor insertion 
while blocking premature cleavage of the signal peptide.  
 
DMSO reductase was one of the first proteins utilizing the Tat apparatus to be studied. 
DMSO reductase is a heterotrimeric redox enzyme composed of the 85.8 kDa DmsA 
(which represents the catalytic subunit and binds a molybdopterin cofactor), the 23.1 
kDa, Fe-S DmsB subunit and the 30.8 kDa DmsC subunit that acts as a membrane 
anchor. DmsA is synthesized with the Tat signal peptide and forms a complex with 




DmsD is the REMP associated with DMSO and plays an essential role in the 
biogenesis and maturation of DmsA (Ray et al 2003). It has been proposed that DmsD 
acWVDVWKHFHQWUDOµ¶KXE¶¶JXLGLQJ'PV$WKURXJKDFDVFDGHRIDFFHVVRU\SURWHLQVIRU
biogenesis. For example, DmsD has repeatedly been shown to have interactions with 
GroEL (the general molecular chaperone implicated in folding/refolding assistance) 
and members of the molybdenum cofactor biosynthesis pathway, especially MoaA 
and MoeB (Li et al 2010, Chan 2015 et al). Similarly, TorD, the REMP associated 
ZLWKPDWXUDWLRQDQGELRJHQHVLVRI7RU$KDVEHHQVKRZQWRµKROG¶GRPDLQV,-III of 
apo-TMAO in a folded conformation while presenting the unfolded MGD 
(molybdopterin guanine dinucleotide) domain, domain IV, to the MGD synthesis 
enzymes (Dow 2013 et al). Acting as a hub not only for MGD insertion into TMAO 
but also for co-ordination of the various enzymes involved in the synthesis of 
molybdopterin and the further step of GMP incorporation to yield MGD. Upon 
binding of MGD, pre-TorA is released to the Tat apparatus for translocation, 
potentially in a GTP-dependent manner (Guymer et al 2010).  
 
Another example is the Nap nitrate reductase in E. coli which is expressed from the 
large operon napFDAGHBC and is an important contributor to the proton gradient 
under anaerobic conditions. Here NapABC form the final periplasmic complex and all 
bind cofactors, where NapA is the nitrate reductase and binds a molybdopterin 
cofactor, while NapC is a quinol oxidase that transfers electrons through NapB to 
NapA (Potter and Cole 1999). NapC and NapB bind tetrahaem and dihaem 
respectively. The only other essential component is the REMP, NapD, which helps to 





Despite having high affinity for cognate signal peptides, REMPs are highly 
promiscuous (Chan et al 2009), aiding targeting and maturation of similar Tat 
substrates, although with reduced efficiency. For example, fusing the HybO signal 
peptide to mature torA and expression of the subsequent gene in ǻWRU' strains still 
correctly localises TMAO to the periplasm, although with ~30% TMAO reductase 
activity. A similar result is obtained when the TorA signal peptide is fused to DmsA 
and expressed in ǻGPV' strains (Chan et al 2009).  
 
Once at the Tat apparatus, a second process takes place, one of proofreading. Various 
studies report the ability of the Tat apparatus to reject substrates with a sufficiently 
destabilised structure (Halbig et al 1999, Maurer et al 2009 and for review see 
Robinson et al 2011), in some cases appearing to target them for degradation (Matos 
et al 2008, Goosens et al 2014). It is not quite clear at what stage this proofreading 
takes place and various studies have sought to determine the exact attribute the Tat 
PDFKLQHU\µVHQVHV¶LQRUGHUWRLGHQWLI\VXIILFLHQWO\IROGHGSUHFXUVRUVBoth native and 
heterologous substrates of the Tat pathway have been used to test the level of accuracy 
of Tat proofreading. For example, the necessity of cofactor insertion was addressed 
with the native Tat substrates NrfC and NapG, both proteins requiring FeS centre 
insertion in the cytoplasm prior to export. Here cysteine ligand sites were substituted 
to block cofactor binding, resulting in abolishment of Tat-mediated export (Matos et 
al 2008). Other studies have focused on the level of conformational stability necessary 
to achieve transport via the Tat pathway. In a study by DeLisa et al (2003) the 
necessity of disulphide formation in substrates was addressed through the use of the 
Sec substrate PhoA, an scFv (antidigoxin) and an FAB fragment. These were fused with 




ǻJRU ǻDSKF ǻGVE$ strains of E. coli (designated Cox, as they have an oxidising 
cytoplasm) and assessed for export competence via the Tat pathway. In this study, 
only expression in Cox strains resulted in protein export to the periplasm via the Tat 
pathway indicating formation of inter- and intra-disulphide bonds is necessary for a 
7DW VXEVWUDWH WR EH µVHHQ¶ DV IROGHG E\ WKH 7DW SURRIUHDGLQJ Pechanism. Slightly 
counter to this, recent studies have shown that both native and heterologous proteins 
targeted to Tat are viable for translocation in apo- and reduced states. A study by 
Alanen et al (2015) identified several heterologous proteins, including human growth 
KRUPRQHK*+DQVF)YDQGDQLQWHUIHURQĮ2ȕ,)1ZHUHH[SRUWHGWRWKHSHULSODVP
via the Tat pathway in the absence of disulphide formation. While neither of these 
studies identified the extent to which disulphide formation contributes to the structural 
stability of the mature protein, it is known that hGH obtains a near-native, active state 
in the absence of disulphides (Bewley et al 1969, Youngman et al 1995). Additionally, 
a study of the E. coli cuprous oxidase CueO, which also binds CuII at several copper 
centres and is a native Tat substrate, revealed translocation occurs with the substrate 
in the apo-form (i.e. without bound copper). The structure of CueO was shown by far-
UV circular dichroism (CD) to be structurally identical in the apo- and mature forms, 
however (Stolle et al 2016). 
Several studies have shown varying lengths of the hydrophilic FG-repeats taken from 
the yeast nuclear pore protein Nsp1p, that intrinsically lack structure, are able to cross 
the bilayer via the Tat pathway when fused to a Tat-specific signal peptide or folded 
proteins in various conformations (Richter et al 2007, Lindenstraub et al 2009, Taubert 
et al 2014). In the earliest of these, translocation efficiency decreased with increasing 
length or until a short hydrophobic stretch was inserted within the FG-repeat chain 




± 205 amino acids lead to late-stage translocation arrest (Lindenstraub et al 2009, 
Taubert et al 2014). These studies show that clearly some form of structural flexibility 
is accepted by the Tat proofreading mechanism and that proofreading possibly only 
takes place immediately before translocation occurs, not throughout the translocation 
process.  
Complementary studies carried out in reconstituted thylakoid systems suggest the Tat 
machinery of thylakoids employ a proofreading process that is less stringent or has 
different criteria to that of the bacterial Tat system. Here Tat-directed substrates with 
inserted FG-repeats or (Gly4/Ser) linkers of up to 75 amino acids successfully 
transported into the lumen, regardless of folding state, at least until a certain size-
threshold was reached (Cline et al 2007). Early studies on the thylakoidal Tat system 
indicated a lack of a proofreading mechanism (Hynds et al 1998), or that it occurred 
on the trans side of the membrane after translocation completion (Roffey and Theg 
1996).     
Other approaches have sought to probe the proofreading process by looking at the Tat 
components themselves. The study published by Rocco et al (2012) used 3-helix-
bundles that had various conformational flexibility fused to TEM-ȕ-lactamase to 
screen for mutations within the TatABC subunits that resulted in a less-stringent 
proofreading mechanism, labelled quality control suppression mutants (QCS). By 
screening for export of a fusion that resembled the molten globule state and was thus 
export-incompatible in wild-type TatABC they identified residues that were key to 
allowing export of Tat substrates with increased conformational flexibility while 
maintaining the ability to reject completely mis-folded proteins. Interestingly the 




TatA, TatB and TatC. The fact that such QCS mutations can be identified proves that 
proofreading is at some level carried out by the Tat translocon.   
A study by Goosens et al (2014) appeared to separate Tat-mediated quality control 
and proofreading by utilising mutagenesis studies. Using the Rieske Fe-S protein, 
QcrA, from the cytochrome bc1 complex of Gram-positive bacteria, they substituted 
Cys residues involved in disulphide bridge formation or His residues needed for 
ligation of cofactor. Whereas cofactor-deficient QcrA was observed stalled at the 
membrane associated with the Tat machinery, QcrA lacking the disulphide was 
degraded in the cytoplasm. These results are interesting as they imply, for Gram-
positive organisms at least, Dµ¶KLHUDUFK\¶¶EHWZHHQGLVXOSKLGHIRUPDWLRQDQGSRVVLEO\
REMP-assissted, cofactor insertion. The study did fail to identify the structural state 
of either of the mutant species however, thus one could be drastically mis-folded over 











1.4 Aims of this project 
While several advances have recently been made into the possible mechanism of 
translocation employed by the twin-arginine translocase, information aided by high-
resolution structures of the TatABC components solubilised in detergents, we are still 
little closer to understanding how exactly the proofreading mechanism functions and 
ZKDWLVµVHQVHG¶LQDVXEVWUDWH 
This study aims to delineate some of the nuances of the Tat proofreading mechanism 
through alterations to surface characteristics and subtle changes to substrate folded 
state.    
The following chapters cover: 
- scFvM targeting to TatABC 
- Maquette BT6 targeting to TatABC 
- hGH comparison via Sec and TatABC 
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2 Materials and Methods 
 
Suppliers of chemicals 
All chemicals used in this study were supplied by Fisher Scientific UK (Thermo Fisher 
Scientific Inc, USA), Sigma (Sigma-Aldrich, USA) or Formedium (UK) unless 
otherwise stated. 
 
2.1 DNA Techniques 
 
2.1.1 Preparation of plasmid DNA 
All plasmids were isolated through mini-preparation using QIAprep spin miniprep kit 
4LDJHQ +LOGHQ *HUPDQ\ DV SHU WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV 3ODVPLGV ZHUH
recovered in 30 µL elution buffer (10 mM Tris-Cl pH 8.5) and concentration 
determined using NanoDrop 2000c (Thermo Fisher Scientific Inc, USA) before use 
immediately or stored at -20°C until needed.  
 
2.1.2 Amplification Polymerase Chain Reaction (PCR) 
PCR solutions were made using 1 µL template DNA (80-100 ng), 1 µL dNTP mix 
(200 µM, Promega, USA), 10 µL GC buffer, 0.3 µL of each primer (0.5 µM), 1.5 µL 
DMSO (3%), 0.5 µL Phusion high fidelity DNA polymerase (2U/µL, New England 
Biolabs, UK) and made up to a final volume of 50 µL with milliQ H2O (GenPure 
UV/UF water purification system). PCRs were generally carried out in Biometra T3 




MATERIALS &  METHODS  
47 
 
An example amplification reaction is given below: 
Initial denaturation      98°C                                30 sec 
Denaturation                98°C                                10 sec 
Annealing                   primer Tm minus 3-5°C    30 sec 
Extension                     72°C                                30 sec 
Final extension            72°C                                 5 min 
Pause                             4°C  
 
2.1.3 Amplification (PCR) Primers 
Table 1 shows all amplification primers used in this study, supplied by Eurofins 
MGW. The nucleotides encoding affinity tags are shown in bold while restriction sites 
are underlined.  
 
2.1.4 Agarose gel electrophoresis 
Agarose gels were prepared by adding 1% (w/v) agarose (Bio-Rad Laboratories Ltd, 
USA) to 50 mL 1x TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA, pH 8.2). After 
mixing, the solution was microwaved at MAX power for a total of 45 seconds with 
occasional swirling until agarose had dissolved. Once set the gel was submerged in 1x 
TAE buffer. DNA samples were mixed with either 4 µL or 10 µL (restriction digest 
or PCR amplification respectively) 6x Gel Loading Buffer (Thermo Fisher Scientific 
Inc, USA) and 2 µL or 4 µL SYBER Green Nucleic Acid Gel stain (20x in DMSO, 
Invitrogen, Thermo Fisher Scientific Inc, USA) and left to sit for 5 min prior to gel 
loading. Electrophoresis was then carried out at 150V for 40 min. DNA was visualised 
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scFvMARO ATG ATG ATG ATG ATG GCG TTT GAT TTC CAC TTT TGT 
ACC  
scFvMBRO  ATG ATG ATG ATG ATG ACG TTT GAT CTC AAC TTC GTG 
CCC  
scFvMERO  ATG ATG ATG ATG ATG ACG TTT GAT CTC AAC CTT CGT 
GCC  
scFvMGRO  ATG ATG ATG ATG ATG ACG TTT GAT TTC AAC TTT GGT 
GCC  
scFvMHRO  ATG ATG ATG ATG ATG TTT TTT GAT TTC CAC TTT GGT 
GCC  
scFvMIRO ATG ATG ATG ATG ATG ACG ACG AAT TTC AAC ACG TGT 
ACC' 






Maquette BT6 study 
TorABT6KpnIF TAA TAA GGT ACC CAT ATG AAC AAT AAC GAT CTC TTT 
TorABT6XbaIR GGC GGC TCT AGA CTC GAG TTA ATG GTG GTG ATG ATG  
BT6KpnIF TAA TAA GGT ACC ATG GCG CAA GCG GCG GGC GGC 
TorABT6XhoIR TTA TTA CTC GAG ATG GTG GTG ATG ATG GTG CAA TTG  
BT6HisXhoIF TAA TAA CTC GAG GCGCAAGCGGCGGGCGGCGACGGC  
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BT6HisXbaIR TTA TTA TCT AGA TTA GGC ATA ATC CGG AAC ATC ATA 
CGG ATA CAG CTG TTT CAG ATC CTC AAA CTG 
 
2.1.5 Purification of DNA from agarose gels 
Appropriate bands were excised from agarose gels under UV transilluminescence 
using a sharp scalpel blade. Agarose was then removed using QIAprep gel extraction 
NLW 4LDJHQ +LOGHQ *HUPDQ\ DV SHU PDQXIDFWXUHU¶V LQVWUuctions. DNA was 
recovered in 30µL elution buffer before use or stored at -20°C until needed.  
 
2.1.6 Restriction Digests of DNA 
Typically, 2 µg DNA was mixed with 1 µL appropriate buffer and 20units 1st 
restriction enzyme and incubated at 37°C for 30 min (AccuBlock digital dry bath, 
Labnet, USA) before adding 20units 2nd restriction enzyme and incubation at 37°C for 
a further 1 hr. Table 2 shows restriction enzymes used in this study. DNA products 
were then isolated through agarose gel electrophoresis and purification as detailed 
previously.  
 
Table 2. Restriction enzymes used in this study. 
Enzyme ^ĞƋƵĞŶĐĞ ? ? ?ї ? ? ? 1st or 2nd  
NdeI CATATG 1st 
BamHI GGATCC 2nd 
KpnI GGTACC 1st 
XbaI TCTAGA 2nd 









2.1.7 Ligation of DNA fragments into plasmid vector backbone 
DNA fragments were cloned into open plasmid vectors using T4 DNA ligase (Roche, 
Sussex, UK). Insert and vector were mixed in a 3:1 ratio (typically 9 µL to 3 µL) with 
1 µL ligase buffer and 1 µL T4 ligase then incubated overnight in Biometra T3 
Thermocycler. The next day 10 µL ligation reaction was used to transform competent 
E. coli '+Į;/%OXHRU1(%7XUERFHlls as described in section 2.2.4. The ligation 
program is given below: 
 
4°C      30 min 
16°C    30 min 
 
2.1.8 Ligation of DNA fragments 
DNA fragments to be joined were mixed in a 1:1 ratio and incubated overnight in 
Biometra T3 Thermocycler on ligation program as detailed in section 2.1.7. The next 
day ligation reaction was subject to agarose gel electrophoresis and appropriate 
fragments purified (section 2.1.4 and 2.1.5). DNA fragments were then amplified 
through PCR (section 2.1.2) and again subject to agarose gel electrophoresis to purify, 
before restriction digest with the appropriate enzymes and ligation into an open 
plasmid vector as described in section 2.1.6 and 2.1.7.  
 
2.1.9 Site-specific DNA mutagenesis 
Point mutations were introduced using Pfu Turbo alongside QuickChange site-
directed mutagenesis kit (Agilent Technologies, Cheshire, UKDVSHUPDQXIDFWXUHU¶V
instructions. QuickChange mutagenesis was carried out in Biometra T3 Thermocycler. 
Afterwards 5 µL of DNA was used to transform competent E. coli '+ĮRU;/%OXH
cells as described in section 2.2.4.  
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2.1.10 Site-specific mutagenesis Primers 
Table 3 shows all amplification primers used in this study, supplied by Eurofins 
MGW. 
 





C TCT CTG CGT CTG GAA GAT ACC GCA GTT TAC TA  
scFvMmutMA88L
R 
CGG TAT CTT CCA GAC GCA GAG AGT TCA TCT GGA  
scFvMmutMS122
LF 
G GTT ACC GTG TTA TCT GGC GGT GGT GGC AGC GG  
scFvMmutMS122
LR 





GCA GTT TAC TAT AGC GCG CGT GAT CTG  
scFvMwtC14R 
(C97S) 
CAG ATC ACG CGC GCT ATA GTA AAC TGC  
scFvMwtC79F 
(C162S) 
GCC ACT CTG TCC AGT ACG CTC TCT TCT  
scFvMwtC79R 
(C162S) 
AGA AGA GAG CGT ACT GGA CAG AGT GGC  
TatABC study 
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TatA-20F2 ACT ATC GCC GAT AAG CAG GCG TAA ACG AAT CAG GAA 
CAG GC 
TatA-20R2 GCC TGT TCC TGA TTC GTT TAC GCC TGC TTA TCG GCG 
ATA GT  
TatA-30F2 CC AGT CAG GAT GCT GAT TTT TAG GCG AAA ACT ATC 
GCC  
TatA-30R2 GGC GAT AGT TTT CGC CTA AAA ATC AGC ATC CTG ACT 
GG 
TatA-40F AGC GAT GAT GAA CCA AAG TAG GAT AAA ACC AGT CAG 
GAT GC 
TatA-40R GCA TCC TGA CTG GTT TTA TCC TAC TTT GGT TCA TCA 
TCG CTC 
TatA-45F2 GGC TTT AAA AAA GCA ATG AGC TAG GAT GAA CCA AAG 
CAG GAT AAA ACC 
TatA-45R2 GGT TTT ATC CTG CTT TGG TTC ATC CTA GCT CAT TGC 





















2.1.11 Sequencing of plasmid DNA 
Sequencing was carried out using Beckman Coulter or GATC sequencing service. 
 
Table 4 all sequencing primers used in this study. 
Primer  Sequence Use 
pTacF GAGCGGATAACAATTTCACACAGG Sequencing pTac 
vectors 
CM_pET23_SEQF AGCTGTTGACAATTAATCGGC Sequencing pET23 
vectors 
 
2.1.12 Constructs generated in this study 
Table 5. Constructs generated and used in this study.  
Plasmid Function Reference 
scFvM study 
pYU49 pET23 based vector with pTac expression of protein 
of interest targeted to Tat via TorA signal peptide. 
Polycistronic expression of codon-optimised Erv1p 
and mature human PDI expression (CyDisCo).  
Matos et al 2014 
pHIA554 pET23 based vector with pTac expression of protein 
targeted to Tat via TorA signal peptide.  
Matos et al 2014 
pHAK13 pYU49 TorA-scFvM wild-type Jones et al 2016 
pAJ15 pHIA554 TorA-scFvM wild-type  Jones et al 2016 
pAJ5 pYU49 TorA- 3SB (L11Q, Q13K, A88E, L112K, 
T114E, S116K) 
Jones et al 2016 
pAJ6 pYU49 TorA-5Lys (L11K, Q13K, A88K, L112K, 
S116K) 
Jones et al 2016 
pAJ7 pYU49 TorA-5Glu (L11E, Q13E, A88E, L112E, 
S116E) 
Jones et al 2016 
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pAJ8 pYU49 TorA-1SB (L112K, T114E) Jones et al 2016 
pAJ9 pYU49 TorA-5R>K (R19K, R87K, R150K, R203K, 
R240K) 
Jones et al 2016 
pAJ10 pYU49 TorA-7K>R (K65R, K76R, K162R, K183R, 
K186R, K235R, K239R) 
Jones et al 2016 
pAJ22 pYU49 TorA-26tail (Additional - 
SNAIIIIITNKDPNSSSVDKLAAALE ' 3' to C-
terminus) 
Jones et al 2016 
pAJ24 pYU49 TorA-2SB (A88E, L112K, T114E, S116K) Jones et al 2016 
pAJ31 pYU49 TorA-4NLeu (Q13L, R19L, K65L, K76L) Jones et al 2016 
pAJ35 pYU49 TorA-5Arg (L11R, Q13R, A88R, L112R, 
S116R) 
Jones et al 2016 
pAJ36 pYU49 TorA-5NLeu (Q13L, R19L, K65L, K76L, 
A88L) 
Jones et al 2016 
pAJ39 pYU49 TorA-6NLeu (Q13L, R19L, K65L, K76L, 
A88L, S116L) 
Jones et al 2016 
pAJ18 pYU49 TorA-scFvM (C97S)  Jones et al 2016 
pAJ19 pYU49 TorA-scFvM (C162S) Jones et al 2016 
pAJ34 pYU49 TorA-scFvM (C97S, C162S) Jones et al 2016 
Maquette BT6 study 
pCM219 pEXT22 Single-copy (1 - 1.5 copies/cell) vector with 
pTac promoter. 
Dykxhoorn et al 
1996 
pKG100 pJexpress414 BT6h2 This study 
pKG101 pJexpress414 RR-BT6h2 This study 
pKG102 pJexpress414 KR-BT6h2 This study 
pKG103 pJexpress414 KK-BT6h2 This study 
pKG104 pJexpress414 BT6h0 (H53A, H88A) This study 
pKG105 pJexpress414 RR-BT6h0 (H53A, H88A) This study 
pAJ21 pEXT22 RR-BT6h2 This study 
pAJ25 pEXT22 RR-BT6h0 (H53A, H88A) This study 
pAJ26 pEXT22 KK-BT6h2  This study 
pAJ27 pEXT22 KR-BT6h2 This study 
pAJ28 pEXT22 BT6h2 This study 
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pAJ29 pEXT22 BT6h0 (H53A, H88A) This study 
pAJ40 pEXT22 RR-BT6h2-BT6h0 (H53A, H88A) This study 
pAJ41 pEXT22 KR-BT6h2-BT6h0 (H53A, H88A) This study 
pAJ44 pEXT22 RR-BT6h2-BT6h2 This study 
pAJ45 pEXT22 KR-BT6h2-BT6h2 This study 
pAJ46 pEXT22 RR-BT6h0 (H53A, H88A) - BT6h2  This study 
pGS01 pEXT22 RR-BT6h1 (H53A) This study 
pGS02 pEXT22  BT6h1 (H53A) This study 
Tat truncation study 
pWM-Tat1 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC 
This study 
pAJ48 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatA truncated by 20 
amino acids 
This study 
pAJ50 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatA truncated by 30 
amino acids 
This study 
pAJ54 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatA truncated by 40 
amino acids 
This study 
pAJ52 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatA truncated by 45 
amino acids 
This study 
pAJ62 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatB truncated by 20 
amino acids 
This study 
pAJ59 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatB truncated by 30 
amino acids 
This study 
pAJ60 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatB truncated by 50 
amino acids 
This study 
pAJ61 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatB truncated by 75 
amino acids 
This study 
pAJ63 pLysSBAD (KasI digest to remove lysozyme) 
Escherichia coli TatABC, TatB truncated by 130 
amino acids 
This study 
human Growth Hormone Quality study 
pAJ13 pHIA554 OmpA-human Growth Hormone This study 
pHAK14 pHIA554 TorA-human Growth Hormone Alanen et al 2015 
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2.2 Growth and Maintenance of E. coli cultures 
 
2.2.1 Glycerol stocks 
All constructs used and generated in this study were stored as glycerol stocks in either 
'+Į;/%OXHRU1(%7XUER E. coli strains. Glycerol stocks were prepared by 
combining 1 part stationary phase culture with 2 parts 50% glycerol, then immediately 
frozen on dry ice and placed at -80°C for storage.  
 
2.2.2 Preparation of competent cells 
A 5 mL LB pre-culture, with appropriate antibiotics (at 1:1000 concentration), was 
inoculated with E. coli strain and incubated overnight at 30°C, 200 rpm in a shaking 
incubator (Multitron Pro shaking incubator, Infors, Switzerland). The next day 10 mL 
fresh LB was inoculated from the pre-culture and incubated at 30°C 200 rpm until 
OD600 = 0.3 ± 0.4 at which point cells were pelleted by centrifugation (Jouan GR4_22) 
at 3000 rpm, 4°C, 10 min. Supernatant was discarded and cell pellet resuspended in 
10 mL ice-cold 100 mM MgCl2 and incubated on ice for 5 min. Cells were re-pelleted 
before resuspending in 1 mL ice-cold 100 mM CaCl2 and stored at 4°C for 1 ± 24 hrs 
before use.  
 
2.2.3 Media 
All liquid cultures were grown aerobically in Luria Bertani (LB) medium (10 g/L 
sodium chloride, 10 g/L tryptone, 5 g/L yeast extract), while Luria Bertani Agar (LBA) 
(10 g/L sodium chloride, 10 g/L tryptone, 5 g/L yeast extract, 10 g/L bacto-agar 
(Becton Dickinson and company, USA)) was used for aerobic growth on plates.  
Antibiotics were added just prior to inoculation of cultures and were used at the 
following concentrations: Ampicillin (100 µg/mL), Kanomycin (50 µg/mL) and 
Chloramphenicol (35 µg/mL). All antibiotics were dissolved in milliQ H2O except 
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Chloramphenicol which was dissolved in Ethanol (Fisher Scientific UK, 
Loughborough, UK).  
 
2.2.4 Transformation of competent E. coli cells 
In pre-cooled 1.5 mL eppendorfs 2 µL DNA (100 ng/µL) was gently mixed with 30 
µL competent cells and incubated on ice for 30 minutes. The cells were then placed in 
a water bath (Grant Instruments, Cambridge, UK) at 42°C for exactly 30 seconds 
before placing back on ice for 5 min. Next 0.5 mL LB was added and cells incubated 
at 37°C for 60 min. After incubation, cells were pelleted at 6500 rpm for 5 min. After 
which 500 µL supernatant was discarded and cell pellet gently resuspended in 
UHPDLQLQJ OLTXLG   / 7RWDO FHOO VXVSHQVLRQ ZDV SODWHG RQ /%$ SODWHV
containing appropriate antibiotic(s) which were incubated in Plate incubator (MLR-
162-PE, Panasonic, Japan) inverted, at 37°C overnight.  
 
 
2.3 Protein production 
 
2.3.1 Culture of E. coli and Plasmid induction 
For fractionation of E. coli cells (section 2.3.2 and 2.3.3), typically 5 mL LB with 
appropriate antibiotics was inoculated and grown aerobically at 30°C, 200 rpm 
overnight. The following day cultures were diluted to OD600 = 0.05 in 50 mL fresh 
LB, and antibiotic, in 250 mL erlynmeyer flask before incubation at 30°C until OD600 
= 0.4 ± 0.6. At this point plasmid(s) were induced. Several vectors were used 
throughout this study: pYU49 (pET23 based) and pEXT22 were typically induced 
with 0.5 mM IPTG while pBAD24 and pWM-Tat0 were induced with 20 µM freshly 
made Arabinose.    
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2.3.2 Preparation of spheroplasts 
Cell cultures were separated into Spheroplast (Sp) and Periplasmic (P) fractions using 
the EDTA/lysozyme/cold osmotic-shock method (Randall and Hardy 1986). After the 
appropriate induction period, typically 3 hrs, cells equal to OD600 = 10 were harvested 
by centrifugation at 3000 rpm, 10 min, 4°C. Supernatant was discarded and the cell 
pellet resuspended in 0.5 mL chilled Buffer 1 (100 mM Tris-acetate pH8.2, 500 mM 
sucrose, 5 mM EDTA) before addition of 0.5 mL chilled milliQ H2O and 40 µL 
lysozyme (from egg-white, 1 mg/mL stock (Sigma Aldrich, UK)) and incubation on 
ice for 5 min. Subsequently 20 µL MgSO4 (1 M stock) was added to stabilise inner 
membrane before pelleting by centrifugation at 14 000 rpm (Eppendorf Centrifuge, 
5417R, Hamburg), 4°C, 2 min. 0.5 mL of supernatant was then collected as the 
Periplasmic fraction (P) and stored at -20°C. Remaining supernatant was discarded 
and the pellet was washed with 1 mL chilled Buffer 2 (50 mM Tris-acetate pH 8.2, 
250 mM sucrose, 10 mM MgSO4) and pelleted by centrifugation at 14 000 rpm, 4°C, 
5 min. Supernatant was discarded and cell pellet resuspended in 1 mL Lysis buffer (20 
mM sodium phosphate pH 7.3) and lysed by sonication (3 x 10 sec, 8 µM (Soniprep 
150 plus, Sanyo Gallenkamp, Loughborough, UK)) and 2 x freeze-thaw cycles before 
addition of 10 µL DNase (10 mg/mL) and storage at -20°C.  
 
2.3.3 Cytoplasm and Membrane separation 
Spheroplasts were prepared as in section 2.3.2, however after washing with Buffer 2 
the cell pellet was resuspended in Buffer 3 (50 mM Tris-acetate pH 8.2, 2.5 mM 
EDTA) and membranes lysed by sonication (6 x 10 sec, 8 µM). Membranes were then 
separated from the Cytoplasm by ultracentrifugation at 70 000 rpm (TL-100 
Ultracentrifuge, TLA 100.3 rotor, Beckman Coulter Inc, USA) 30 min, 4°C. 
Following this 0.5 mL supernatant was taken as the Cytoplasmic fraction (C) and 
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remaining supernatant discarded before resuspending the pellet in 0.5 mL Buffer 3 as 
the Membrane fraction (M).   
 
2.3.4 Separation of Insoluble fraction 
To separate insoluble fraction (I) from membrane fraction (M) samples were spun at 
14 000 rpm for 15 minutes, 4°C after the sonication step. The supernatant was drawn 
off and fractionation continued from the ultracentrifugation step (section 2.3.3).  
 
2.3.5 Time course assay 
To generate time courses of protein production and export to the periplasm, samples 
equal to OD5 were taken from 50 mL cultures at appropriate time-points after 
induction. Fractionation was carried out as detailed in section 2.3.2 and 2.3.3.  
 
 
2.4 Protein purification 
 
2.4.1 Immobilised Metal Affinity Chromatography (IMAC), Nickel 
For purification of 6x Histidine-tagged (C-term) proteins by Nickel IMAC, 10 mL LB 
with appropriate antiobiotic(s) was inoculated and grown aerobically overnight at 
30°C, 200 rpm. The next day cultures were diluted to OD600 = 0.05 into 400 mL fresh 
LB and antibiotic(s) in 2 L erlynmeyer flask and incubated at 30°C, 200 rpm. 
Plasmid(s) were induced with 0.5 mM IPTG when culture OD600 = 0.4 ± 0.6 and then 
incubated at 30°C, 200 rpm for 4 hours. After the induction period, cells were 
harvested by centrifuge 3000 rpm, 30 min, 4°C (Beckman Avanti J-25, JA 10 rotor). 
A sample of the supernatant was taken (Media) and the rest discarded. Cell pellet was 
resuspended in 10 mL chilled Buffer 1 without EDTA (so as not to interfere with 
IMAC down-stream, 100 mM Tris-acetate pH8.2, 500 mM sucrose) and 10 mL milliQ 
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H2O before adding 800 µL lysozyme and incubating on ice for 10 min. To stabilise 
membranes 800 µL MgSO4 was added and ½ crushed tablet Complete EDTA-free 
protease inhibitor before centrifugation 14 000 rpm, 20 min, 4°C (Beckman Avanti J-
25, JA 25.5 rotor). Supernatant was taken as the Periplasmic fraction and stored at 
4°C. The remaining pellet was resuspended in 10 mL 50 mM sodium phosphate pH 
7.2, 150 mM NaCl and sonicated (6x 10 sec) before adding 400 µL DNase and frozen 
at -80°C as the Spheroplast.  
Prior to IMAC purification, Spheroplast samples were spun for 20 min 5000 rpm and 
the cell pellet discarded, the supernatant was further spun at 45 000 rpm for 20 min to 
remove unbroken cells and cell debris.   
IMAC columns were run on the same day as Spheroplast/Periplasm fractionation. A 
bed volume of 5 mL IMAC sepharose 6 fast-flow (GE Healthcare, Buckinghamshire, 
UK) beads were added to a 20 mL syringe with glass wool used as a filter. Storage 
solution (20% ethanol) was washed off with 10 column volumes (CV) milliQ H2O 
before adding 5 mL 0.2 M NiCl, followed by another 2CV milliQ H2O wash. Columns 
were equilibrated with 3CV Equilibration buffer (50 mM sodium phosphate pH 7.2, 
0.3 M NaCl) before loading Periplasmic sample and collecting Flow Through (FT). 
Unbound matter was removed with 6CV Wash buffer (50 mM sodium phosphate pH 
7.2, 50 mM Imidazole, 0.3 M sodium chloride) and sample collected as Wash (W). 
Finally 6x Histidine-tagged protein was eluted in 9 x 2 mL fractions of Elution buffer 
with an imidazole gradient (50 mM sodium phosphate pH 7.2, 0.3 M NaCl with 100 
mM, 150 mM, 200 mM or 250 mM Imidazole).  
All samples (Media, Sp, P, FT, W, E1-9) were run on SDS-PAGE (section 2.5.1 and 
2.5.2) and western blot (section 2.6.1) to find peak elution fractions, these were 
assessed for their purity and concentrated.  
MATERIALS &  METHODS  
61 
 
2.4.2 Protein quantification assay 
Proteins were quantified by a Bradford assay (Bio-Rad DCTM Protein Assay, Herts, 
8. DV SHU PDQXIDFWXUHU¶V LQVWUXFWLRQV 2U E\ UHDGLQJ $280 from a quartz cuvette 
(Starna Scientific Ltd, Essex, UK) and using the molar extinction co-efficient to 
calculate concentration.   
 
2.4.3 De-salting IMAC peak fractions 
3HDN ,0$& HOXWLRQ¶V ZHUH SRROHG LQ GLDO\VLV WXELQJ 6QDNH6NLQ GLDO\VLV WXELQJ
Thermo scientific) and dialysed overnight into 50 mM sodium phosphate, 150 mM 
sodium chloride.  
  
2.4.4 Concentrating IMAC peak fractions 
After dialysis, proteins were concentrated with VIVASPIN 20 10,000 MWCO 
columns (Sartorius, Gloucestershire, UK) until an appropriate volume was reached, 
typically 0.25 ± 0.5 mL. 
 
2.5 Protein separation 
 
2.5.1 SDS poly-acrylamide gel electrophoresis (SDS-PAGE) 
Protein separation was carried out using a vertical gel apparatus from Bio-Rad Mini-
PROTEAN® Tetra System (UK), the gels were cast and run according to 
manufactures instructions. Typically, 0.75 mm gels were used, however the Maquette 
work presented in chapter 4 (p. 96) use 1.5 mm gels. The separation gel was composed 
of: 15% acrylamide, 0.3% bis-acrylamide (37.5:1, BioRad, Herts, UK), 375 mM Tris-
HCl pH 8.85 and 0.1 % SDS. Stacking gel was composed of:  5% acrylamide, 0.0375 
% bis-acrylamide 125 mM Tirs-HCl pH 6.8 and 0.001% SDS. Before loading, samples 
were mixed with protein gel loading buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 
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6'6EURPRSKHQROEOXHȕ-mercaptoethanol) and heated for 10 minutes 
at 50°C. Protein gel running buffer was 25 mM Tris, 192 mM Glycine and 0.1% SDS 
at a pH of 8.3. Gels were run until the dye-front had run off the gel, typically 40 
minutes at 60 mA.  
 
2.5.2 Detection of proteins with Coomassie  
The protein profile of samples was visualised with Coomassie stain (0.05% w/v 
Coomassie Brilliant Blue R-250 (Bio-Rad, Herts, UK), 50% Ethanol, 1.74 M Acetic 
acid). Newly run SDS gels were covered in Coomassie stain and incubated at room 
temperature for 1 hr. Stain was subsequently removed and excess removed from the 
gel by incubation with D-stain (5% Ethanol, 7.5% Acetic acid).   
 
 
2.6 Protein imaging 
 
2.6.1 Western-blotting 
After SDS-PAGE visualisation of C-terminal 6x His- or C-terminal HA-tagged protein 
was achieved by the wet-western-blot method. Protein was transferred to PVDF-
membrane (GE Healthcare, Buckinghamshire, UK) running for 1 hr at 80V, 
submerged in wet-blot transfer buffer (192 mM Glycine, 25 mM Tris, 10% ethanol). 
Membrane was prepared by soaking in methanol prior to contact with the gel. After 
transfer, PVDF membrane was then immersed in blocking milk (2.5% (w/v) skimmed 
milk powder in 50 mL 1x PBS-tween20 (0.1%)) or 3% BSA solution at 4°C overnight.  
 
2.6.2 Detection of proteins by immunoblotting 
The following day blocked membrane was washed 3x 5 min with 1x PBS-tween20 
(0.1%) before incubating primary antibody (in 20 mL 1x PBS-tween20 (0.1%), 3% 
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(w/v) BSA (Life technologies, CA, USA)) for 1 hour at room temperature on shaking 
table (GyroTwister, Labnet, New Jersey, USA). Membranes were then washed for 3x 
5 min with 1x PBS-tween20 (0.1%) before incubating with secondary antibody (in 20 
mL 1x PBS-tween20 (0.1%)) for 1 hour at room temperature on shaking table. Finally, 
membranes were washed for 8x 5 min with 1x PBS-tween20 (0.1%) before imaging. 
Antibodies and their concentrations used in this study are shown in Table 6. 
Immunoreactive bands were detected using enhanced chemiluminescence detection 
kit (ECL, Bio-5DG+HUWV8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶V LQVWUXFWLRQVBands 
were visualised using BioRad Gel-doc chemiluminescence imager and associated 
software. Comparison of band-intensity was also carried out on BioRad Gel-doc 
imager with appropriate software.    
Table 6. Antibodies used in this study. 
Primary 
antibody 




1 in 8000 Invitrogen anti-Mouse-HRP 1 in 5000 Promega 
anti-HA (C-
term) 
1 in 1100 Sigma anti-Rabbit-HRP 1 in 5000 Promega 
anti-TatA 1 in 2000 Laboratory stock 
(Bolhuis et 
al2000) 
anti-Rabbit-HRP 1 in 5000 Promega 
anti-hGH 1 in 10 000 Laboratory stock 
(Alanen et al 
2015) 
anti-Rabbit-HRP 1 in 5000 Promega 
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The Tat system of Escherichia coli consists of the three membrane proteins, TatA, TatB 
and TatC and is the most well-understood TatAC-like system. The TatABC system 
functions in the cell membrane of E. coli to transport proteins across the plasma 
membrane. Tat substrates generally preclude export via Sec due to one of several reasons 
± rapid folding, co-factor binding or oligomerisation (Berks et al 2003, Rodrigue et al 
1999, Wu et al 2000). Substrates are targeted to the Tat pathway via an N-terminal signal 
peptide which is then cleaved upon successful translocation (Stanley et al 2000), as 
discussed in section 1.1. Evidence suggests the Tat pathway has a proofreading 
mechanism to ensure incorrectly folded proteins are not translocated (section 1.3.6). A 
multitude of studies have sought to probe the mechanism by which Tat proofreads 
substrate wherein sufficient destabilisation of substrate structure results in 100% rejection 
by the Tat system (Halbig et al 1999, DeLisa et al 2003, Richter and Brüser 2005, Matos 
et al 2008). Initial studies in this area utilised the native E. coli protein alkaline 
phosphatase (PhoA) fused with a Tat-specific signal peptide (TorA), to show that without 
prior formation (i.e. in the cytoplasm) of disulphide bonds, these proteins were rejected 
for export via the Tat pathway (DeLisa et al 2003). Fortunately the Tat proofreading 
system is capable of functioning on heterologous proteins that it would not normally 
encounter in nature. Thus further studies utilised heterologous recombinant proteins (e.g. 
hGH, interferons and scFvs) to probe the Tat proofreading mechanism (DeLisa et al 2003, 
Alanen et al 2015). These further highlighted the ability of the Tat system to distinguish 
between folded and mis-folded substrates. The majority of these studies however, utilised 
either grossly mis-folded substrates or substrates for which the degree of miss-folding is 
XQFOHDUDQGWKXVLWLVGLIILFXOWWRSLQSRLQWH[DFWO\ZKDWLWLVWKDW7DWµVHQVHV¶ DVµXQIROGHG¶. 
Here we have sought to assess the proofreading mechanism of the Tat system through the 
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use of a biotechnologically relevant protein fused with a Tat targeting signal at the N-
terminus. 
 
VF)Y¶VDUH ideal candidates to probe the proofreading capacity of the Tat system as they 
are heterologous, they usually contain disulphide bonds and they are the initial step to the 
recombinant production of large, complex molecules such as bi-specifics and antibodies 
(e.g. IgGs). Here, we have taken an scFv (named scFvM) developed for use in a solubility 
study (Austerberry et al 2017) and used it to probe the proofreading capacity of the Tat 
system on a more nuanced level. The primary sequence of scFvM is shown in Figure 6 
where various features are highlighted (e.g. bridge-forming cysteine pairs, TorA signal 
peptide and 6x histidine-tag). The rationale behind this study is two-fold ± we have a 
number of scFvM variants for which the Tm, peak fluorescence and secondary structure 
(through CD) have been determined, thus for the first time we can probe the Tat system 
with substrates of defined structure. Second, the effect of structural flexibility can be 
observed through the export competence of the reduced and oxidised forms. 
 
We first tested the necessity of prior disulphide formation on export for scFvM by 
expressing it in wild-type and CyDisCo strains. The cytoplasm of E. coli is naturally 
reducing, which inhibits the formation of disulphide bridges. Recently this has been 
overcome through the expression of a yeast mitochondrial thiol oxidase (Erv1p) and 
human protein disulphide isomerase (hPDI), collectively termed CyDisCo (Cytoplasmic 
Disulphide formation in E. Coli), in the cytoplasm of E. coli alongside protein(s) of 
interest (Hatahet et al 2010, Nguyen et al 2011). Second we created three groups of 
mutants designed to probe the proofreading mechanism of the Tat apparatus through 
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Figure 6: Primary amino acid sequence and structural features of scFvM. The scFv in this 
study was fused to the signal peptide from TMAO reductase (yellow) along with the first four 
amino acids of the mature TMAO protein (green). Numbering starts at the first methionine 
residue of the mature scFv with residues forming restriction sites from NdeI and BamHI shown 
in italics. Bridge-forming cysteine residues are shown in orange and underlined (Cys23-Cys97 
and Cys162-Cys232), while the (Gly4/Ser)3 linker between immunoglobulin domains is bold 
and underlined. The C-terminal 6x histidine-tag is shown in brown.  
modifications to the surface charge of scFvM while having minimal effect on the 
secondary or tertiary structure. These groups are: 1) substitution of 2, 4, or 6 non-polar 
residues to create 1, 2 or 3 surface salt-bridges formed of Lys-Glu pairs. 2) Substitution 
of 5 non-SRODUUHVLGXHVZLWK/\V*OXRU$UJWRFUHDWHDFRQFHQWUDWHGµSDWFK¶RIFKDUJH
and finally, substitution of surface Lysines with Arginines or Arginines with Lysines to 
represent a more distributed charge. 
 
Richter et al (2007) used short chains of hydrophilic FG repeats, some interspersed with 
a hydrophobic stretch to suggest the Tat system proofread by identifying exposed 
hydrophobic regions, thus we created a fourth group of scFvM variants where 4, 5 or 6 
















scFvM is folded and active in the reduced form but is exported by Tat more efficiently in 
the oxidised form 
In this study we aimed to get a more discerning view of the Tat proofreading capacity. To 
this end we chose a biotechnologically-relevant model protein as a substrate for which 
we had a well-defined structure along with multiple variants thereof. These variants had 
either altered surface features while maintaining tertiary structure, or the folding and thus 
tertiary structure was deliberately disrupted. Some of the variants with altered surface 
features are sourced from a biophysical study on the scFv in solution (Edwardraja et al 
2010, Austerberry et al 2017), these are summarised in Table 7. The scFv is raised against 
c-Met, a protein which plays an important biological role in the proliferation of cancer 
cells (Edwardraja et al 2010). Although there is no crystal structure available, scFvM is 
homology modelled to PDB file 2GHW and is comprised of two immunoglobulin folds 
FRQQHFWHGE\DVKRUWµOLQNHU¶UHJLRQWUDGLWLRQDOO\XVHGLQVF)Y¶V*O\4Ser)3) (Miller et al 
2010), shown in Figure 7 from two projections as a ribbon diagram, with surface potential 
and finally with surface hydrophobicity. Each domain contains a disulphide bond 






CHAP TER 3:  SCFVM 
71 
 
Figure 7: Ribbon, surface potential and surface hydrophobicity images of scFvM from 
two projections. Top panel: projection centred on patch that is uncharged in the wild-type. 
Bottom panel: projection centred on N-WHUPLQDO5LEERQGLDJUDPȕ-VKHHWV OLJKWJUHHQĮ-
helix = gold, loop regions = grey. Disulphide bridges are circled in red. Surface potential: blue 
= positive, red = negative, grey = uncharged/neutral. The uncharged patch where salt-bridge 
or charge substitutions are located is circled in green. Hydrophobic surface: purple = 












5LEERQ 6XUIDFHSRWHQWLDO +\GURSKRELFLW\ 
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Previous studies have shown that although the TatABC system has a discerning 
proofreading mechanism, some Tat-targeted heterologous proteins do not require prior 
formation of their disulphide bonds before export (Alanen et al 2015) and are thus less 
likely to be in a dynamic state i.e. they are rigid. These proteins are known to take on their 
native conformation, be stable and are active without formation of these disulphides 
(Bewley et al 1969, Youngman et al 1995). In light of this, we first tested the necessity 
of prior disulphide formation for export of scFvM, even though this protein is also soluble 
and active in the reducing cytoplasm of E. coli (Edwardraja et al 2010, Austerberry et al 
2017). We verified the reduced state of the disulphide bonds in the E. coli cytoplasm and 
during purification through mass spectrometry analysis of scFvM immediately after 
purification with and without the addition of the reducing agent DTT. The resulting data 
show a mass that corresponds to the reduced state of 26, 806 Da in both cases, shown in 
Figure 8, and thus the biophysical/activity data presented here (see below) were carried 
out on the reduced form of scFvM.  
 
scFvM was fused with a TorA signal peptide (similar to other studies on the Tat system 
e.g. Thomas et al 2001, shown highlighted in yellow in Figure 6) and expressed either in 
the presence or absence of the CyDisCo components, as a previous report by our group 
has shown a different scFv does not require formation of disulphide bonds prior to export 
(Alanen et al 2015). Figure 9.A and B show time-course analysis of export after induction 
with IPTG. An equivalent amount of cells were fractionated into cytoplasm, membrane 
and periplasm (C/M/P) after the time periods indicated in the wild-type strain (Figure 
9.A) where the cytoplasm is reducing (i.e. in the absence of CyDisCo components). 
Protein is evident in all three fractions after 2 hr with a gradual build-up observed over 
the 5 hrs shown. The band in the periplasmic fraction (P) 
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Figure 8: Mass Spec data verifying reduced state of purified scFvM used for biophysical 
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indicates scFvM is exported by the Tat system in the reduced form. However the strength 
of this band compared to the cytoplasmic and membrane bands at this time-point indicates 
export of the reduced form is very inefficient. A precursor band can be seen at a higher 
molecular weight (32.3 kDa) which corresponds to unprocessed TorA-scFvM. The lower 
molecular weight bands correspond to the mature size scFvM (26.8 kDa) and the presence 
of these in the cytoplasm and membrane fractions is likely due to clipping by cytosolic 
proteases; this phenomenon is often observed when overexpressing Tat-targeted protein 
in strains with native levels of the Tat machinery.  
Figure 9.B shows a parallel time-course analysis of scFvM strains co-expressing the 
CyDisCo components, here the same build-up of protein is observed over the period 
shown. However, even from the first time point bands corresponding to mature scFvM 
are much more prominent indicating a larger quantity of protein present. The build-up of 
mature protein in the periplasmic fraction (P) is more evident in CyDisCo expressing 
cells. To confirm the observed band intensities are not just a between-gel artefact, the 
bands from multiple experiments were subject to densitometry from the same gel. This 
revealed that export is circa 10x more efficient in CyDisCo expressing cells (see Figure 
9.D and Figure 14, discussed more below).  
scFvM contains two disulphide bridges, one in each immunoglobulin fold. These are 
formed between Cys23±Cys97 and Cys162±Cys232 (orange in Figure 6 and circled in 
the ribbon diagram of Figure 7). In order to further test the necessity of disulphide 
formation upon export, Cysteine residues were substituted with Serine to break each 
bridge individually and both bridges at the same time (denoted C97S, C162S and Dual 
Cys respectively). These were co-expressed alongside CyDisCo as export is more 
efficient and Figure 9.C shows fractionation of these cells after 3 hrs. Here it can be seen 
breaking either disulphide has a similar effect to expression in wild-type cells (i.e. without 
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Figure 9: Expression of TorA-scFvM (unmodified and Cysteine variants) with or without 
CyDisCo. A & B: Expression of TorA-scFvM in wild type or CyDisCo cells with 
fractionation into Cytoplasm (C), Membrane (M) and Periplasm (P) after 2 hrs, 3 hrs or 5 hrs 
induction. C: Expression of cysteine variants that could no longer form one or both disulphide 
bridges in CyDisCo cells. D: Comparison of Total cell (TC) and Periplasm samples for 
expression of scFvM with (+) or without (-) CyDisCo components. In all cases samples were 
immunoblotted to the C-terminal 6x histidine-tag. Mobility of precursor and mature forms of 
scFvM are shown on the right, while molecular weight markers are shown on the left.  
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Finally, Figure 9.D shows the periplasm from scFvM expressed in CyDisCo or wild-type 
cells run adjacent to total cell (TC) extract that was not fractionated. This helps to 
highlight the difference in efficiency of scFvM export in oxidising and reducing cells and 
also confirms that export efficiency is comparable to that observed as a proportion of the 
combined (C+M+P) samples.  
Altogether these results indicate export of scFvM by the Tat system is far more readily 
tolerated in CyDisCo expressing cells in which cysteine residues are able to form 
disulphides, an interesting result considering scFvM is suitably folded after extraction 
from the cytoplasm of wild-type cells (discussed below) and we propose that formation 
of the disulphide bonds generates a more rigid substrate structure that is more acceptable 
to the Tat proofreading mechanism.  
 
The Tat proofreading mechanism is tolerant of large-scale alteration to substrate surface 
charge 
Evidence suggests the Tat system may prefer certain surface characteristics in a substrate, 
with certain surface features being equated with unfolded protein and thus rejected for 
export (for example, a large area of hydrophobicity may indicate incomplete folding) 
(Richter et al 2007). To assess this point we altered the surface charge or hydrophobicity 
while ensuring the structure remained unaffected. These scFvM variants with altered 
surface residues were then fused with a TorA signal peptide and tested for export via the 
Tat system. As previously mentioned, the initial surface alterations can be grouped into 
three groups: 1) 2, 4 or 6 uncharged residues were substituted to form 1, 2 or 3 surface 
salt-bridges (SB) composed of Lys-Glu pairs and these were denoted 1SB, 2SB and 3SB 
respectively. 2) 5 uncharged surface residues (L11, Q13, A88, L112 and S116) were 
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VXEVWLWXWHGZLWK/\V*OXRU$UJ WRFUHDWHD µFKDUJHGSDWFK¶ DVKLJK OHYHOVRI VXUIDFH
charge have been shown to reduce aggregation (Lawrence et al 2007) and this could be a 
factor in improving export. These are denoted 5Lys, 5Glu and 5Arg respectively. 3) 
Finally, several surface arginines were substituted with Lysine (5R>K) or vice versa 
(7K>R), to test if the identity of surface positively charged side-chains effected export. 
The substitutions in groups 1 and 2 are located in a region which is uncharged in the wild-
type while group 3 substitutions are distributed globally across the surface of scFvM.  
Surface images displaying electrostatic potential of group 1 and 2 variants are shown in 
Figure 10 with positive charge in blue, negative charge in red and uncharged in grey. The 
top row shows salt-bridge variants with increasing number of salt-bridges from left to 
right (1SB, 2SB, 3SB), with each successive salt-bridge indicated by arrows. The image 
on the far-left details the wild-type scFvM with the uncharged region circled. In the 
ERWWRPSDQHOJURXSYDULDQWVDUHVKRZQZLWKWKHµFKDUJH-SDWFK¶FLUFOHGWKHVDPHDUHD
circled in the wild-type. Images from left to right are 5Lys (blue), 5Glu (red) and 5Arg 
(blue), and it can be seen that a significant area of charge has been introduced.  
 
The variety of mutant versions of scFvM analysed in this study have wide ranges of 
surface charge and this could alter the individual variants¶ proclivity to be correctly 
separated by the fractionation protocol used. For this reason control experiments were 
consistently carried out to ensure the levels of protein in each of the fractions is an 
accurate representation of the intact cell. A sample of these is shown in Figure 11. Figure 
11.A shows a Coomassie-stained gel of the cytoplasm, membrane and periplasmic 
fractions from a 3 hr induction of scFvM expressed alongside CyDisCo. It is easily 
evident that the protein profiles of each fraction are distinct.  
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Figure 10: Structures of scFvM variants with introduced surface salt-bridges (SB) or 
patch of charge. Top row, from left: unmodified scFvM with uncharged domain circled in 
green. Incremental salt-bridges are shown from right to left with each new salt-bridge 
indicated by green arrows. Salt-bridges are formed from Lys-Glu pairs. Bottom row, from left: 
unmodified scFvM with uncharged domain circled in green. Patches of 5x Lys, Glu or Arg are 
shown from left to right. Blue = positively charged at physiological pH. Red = negatively 
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Figure 11: Fractionation controls for scFvM export assays. TorA-scFvM was expressed in 
CyDisCo cells and ǻWDW$%&'( strains. After 3 hr induction, cultures were fractionated into 
Cytoplasm, Membrane and Periplasm fractions. A: Coomassie-stained gel highlighting the 
distinct protein profile of C/M/P fractions. B: Immunoblot for fractionation of cells expressing 
TorA-scFvM and CyDisCo or in tat null strains (left and right lanes respectively). The central 
lanes show fraction of cells expressing a 26tail variant (Figure 16). Mobility of molecular 
markers (in kDa) are shown on the left, while precursor and mature forms of scFvM are shown 
on the right.  
Figure 11.B shows a western blot for fractionation of scFvM expressed alongside 
CyDisCo and a tat null strain: a periplasmic band is apparent in the former but completely 
absent in the latter, demonstrating there is no leakage of cytoplasmic or membrane 
fractions into the periplasmic fraction. The tat null fractionation is also important as it 
also demonstrates proteolytic processing of TorA-scFvM to the mature size in the 
cytoplasm. Figure 11.B also shows fractionation of an scFvM mutant termed 26tail 
(discussed in more detail below) expressed alongside CyDisCo; again the absence of a 
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Figure 12: Coomassie-stained gel of scFvM variants purified by protein A affinity 
column. Molecular weight markers are shown on the left (in kDa) with mature protein 








































Before testing these mutations for the effect on export by the Tat system, we wanted to 
ensure none had introduced any significant structural changes, thus variants were 
expressed and purified from the cytoplasm of wild-type cells (i.e. cells not expressing 
CyDisCo) and biophysical characterisation of the variants undertaken. The characteristics 
of the wild-type and variants are shown in Table 7. Purification from the cytoplasm of 
wild-type cells and biophysical characterisation was carried out by James Austerberry at 
the University of Manchester. Biophysical studies were carried out on the reduced 
protein, indicated by the mass spectrometry data, whereas export assays were conducted 
in cells co-expressing CyDisCo components because export is more efficient. 
Nevertheless, the reduced protein is folded, thus it is reasonable to assume disulphide 
bond formation by the CyDisCo components would only serve to decrease the structural 
flexibility of the domains, increasing rigidity and will not alter the tertiary structure or 
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Inspection of Table 7 reveals that each of the variants in groups 1, 2 or 3 share a high 
degree of structural similarity to the wild-type scFvM deviating by, at most, 0.03 from 
wild-type values; a negligible amount. Fluorescence peak values deviated by no more 
than 0.6 nm from the wild-type peak of 334.6 nm and had a hydrodynamic radius with a 
maximum of 0.2 nm difference to the wild-type of 2.4 nm. Fluorescence peak and 
hydrodynamic radius give an indication of overall compactness of a protein, providing an 
indication of globular density and flexibility. In order to conduct these biophysical 
experiments on scFvM and associated variants, protein first needed to be purified. After 
expression in the cytoplasm, protein was purified via Protein A affinity chromatography. 
Figure 12 shows a Coomassie stained SDS-PAGE for samples of the elutates from the 
Protein A column. All variants have a band similar to that of the wild-type. This is 
significant as Protein A affinity requires an intact VH domain-fold, confirming all variants 
have an intact Protein A binding site and a structural character similar to the wild-type. 
The combination of biophysical data and ability to bind a Protein A column of the variants 
presented here serve to confirm the surface variations have minimal effect on overall 
tertiary structure of scFvM and substantiate continuation of this study.  
 
As with the wild-type, all variants were cloned into vector pYU49 (TorA signal peptide 
and co-expression of CyDisCo) and plasmids were induced with 0.5 mM IPTG for 3 hrs 
before fractionation into cytoplasm, membrane and periplasm. Figure 13 shows the 
results of these fractionations after western blotting to the C-terminal 6xHis-tag. Figure 
13.A shows introduction of 1, 2 or 3 Lys-Glu salt-bridges to the surface results in an 
export profile with little difference to the wild-type ± a band at mature size (26.2 kDa) is 
prominent in the periplasm (P) with mature (32.3 kDa) and precursor bands present in the 
cytoplasm and membrane. With a cursory glance it could be argued that 2SB and 3SB 
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Table 7: Structural characteristics of scFvM variants characterised by circular 
dichroism, tryptophan fluorescence and dynamic light scattering. Secondary structural 
elements were obtained through fits of the spectra between 190 ± 260 nm by CDNN secondary 
structural analysis programme. Samples are at a concentration of 1 mg/mL as determined by 
UV absorbance at 280 nm, in 25 mM sodium acetate buffeUS+Į5 UHJXODUDOSKDKHOL[
Į' GLVRUGHUHGDOSKDKHOL[ȕ5 UHJXODUEHWD-VKHHWȕ' GLVRUGHUHGEHWDVKHHW7 EHWD
turns, U = unordered. Secondary structural fractions are rounded. Work contributed by James 
Austerberry at University of Manchester.   
show slightly improved export over the wild-type, however after comparison of several 






it is evident that all three salt-bridge variants are exported to a degree broadly similar to 
the unmodified scFv. Figure 13.B shows fractionation for variants 5Lys, 5Glu and 5Arg. 
Bands appear to be weaker overall, however further tests show that 5Lys and 5Glu are 
still exported with moderate efficiency (export efficiency is discussed in more detail 
EHORZ 7KH LQWURGXFWLRQ RI DQ µDUJLQLQH SDWFK¶ LQ WKH $UJ YDULDQW KRZHYHU JUHDWO\
reduces export efficiency, evident here by a comparatively weak band in the periplasm 
(P).  
Figure 13.A and B also show a control export of the unmodified scFvM run against total 
cells (TC) to show the combined (C+M+P) samples are representative of a total cell. 
These panels also show scFvM total cell sample before induction (U), where the absence 
Mutant pI 
Secondary Structural Element Fluoresence 
Peak [nm] 
Hydrodynamic 
Radius [nm] ĮR ĮD ȕR ȕD T U 
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of band confirms expression of scFvM from this plasmid is tightly regulated by the 
presence of IPTG. Figure 13.C shows similar controls for scFvM group 1 and 2 variants 
with total cell samples run adjacent to periplasmic samples. Not only are the export 
efficiencies comparable to those in panels A and B, but Figure 13.C also serves to 
highlight the reduced export efficiency of the 5Arg variant.  
 
Due to the poor export efficiency observed for the 5Arg variant, we tested whether the 
Lys:Arg ratio and distribution of positively charged side-chains affected export by 
substituting these residues in other places across the scFvM surface. To this end 5 arginine 
residues were substituted with lysine in 5R>K (note these are different residues to those 
in variant 5Arg) and 7 lysine residues were substituted with arginine in 7K>R. These 
substitutions account for all of the surface exposed Arg/Lys residues. Export assays for 
these two variants are shown in Figure 13.D, revealing that 5R>K and 7K>R are both 
exported with reasonable efficiency and thus it is likely the reduced export observed in 
$UJLVQRWGXHWRDQµDYHUVLRQ¶WRDUJLQLQHRQWKHSDUWRIWKH7DWPDFKLQHU\GLVFXVVHG
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Figure 13: Export assays for salt-bridge and charged patch scFvM variants. A: Export 
assay for unmodified scFvM and salt-bridge variants where 2, 4 or 6 surface residues were 
substituted to form 1, 2 or 3 salt-bridges (1SB, 2SB, 3SB) formed of Lys-Glu pairs 3 hrs after 
induction. Samples were generated as in Figure 9 and were run against Total Cell (TC) and an 
equivalent number of cells prior to induction (U). B: Export assay for the charge patch variants 
where 5 residues were substituted to introduce 5x Lys, Glu or Arg residues. Shown in the same 
format as in A. C: Total cell and Periplasmic samples from unmodified and all variants were 
run on the same gel for comparison. D: Export assays for unmodified scFvM and variants in 
which 5 surface arginines were substituted with lysine or 7 surface lysines were substituted 
with arginine. Molecular weight markers are shown on the left (in kDa) while precursor and 
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Figure 14: Export efficiencies calculated for the scFvM variants used in this study. After 
each export assay, the signal strength of each periplasmic band was calculated as a percentage 
of the total strength of bands for that variant (C+M+P). Shown is the average from 4 separate 
export assays per variant with export efficiency relative to that of the unmodified variant. 
scFvM +/- = TorA-scFvM unmodified expressed with or without CyDisCo components 
respectively.  
To more accurately compare the export efficiency of the individual scFvM variants, the 
bands on the blots for multiple repeat experiments were subject to densitometry and 
compared to the export efficiency of the wild-type. Figure 14 shows the average export 
efficiencies calculated after 4 separate experiments, relative to the wild-type. Here it 
becomes apparent that introduction of up to 3 Lys-Glu salt-bridges has minimal effect on 
export efficiency, while a patch of 5Lys or 5Glu residues is moderately tolerated. 
However, creation of a 5Arg patch greatly reduces export efficiency. Counter to this, 
exchanging surface lysines with arginines or vice versa does not drastically affect export, 
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The Tat system can tolerate significant surface hydrophobicity in substrates 
Previous studies have suggested that hydrophobicity in a substrate could be a key factor 
in how the Tat machinery assesses the folding state (Richter et al 2007), with high levels 
of hydrophobicity equated with an unfolded protein as these are usually sequestered 
within the interior. In continuation of our alteration to the surface features, we created 
another group of variants where 4, 5 or 6 hydrophilic surface residues were substituted 
with leucine. These variants are denoted 4NLeu, 5NLeu and 6NLeu respectively, with 
substitutions beginning in the N-terminal domain. The top panel of Figure 15 shows 
hydrophobicity profiles, centred on the N-terminal domain of group 4 variants compared 
to the wild-type (left). The surface of the unmodified scFvM is predicted to be relatively 
hydrophilic with hydrophobicity (shown in yellow, hydrophilic residues are purple) 
contributed by alanines, two valines and a leucine, therefore introducing multiple leucine 
residues to the surface will likely significantly increase the hydrophobicity of this region. 
Unmodified scFvM is shown on the left with pre-existing hydrophobic residues labelled. 
4NLeu, 5NLeu and 6NLeu are then shown with additional Leu residues arrowed in each 
case. It should be noted that structural characterisation of this group of variants was not 
possible as they could not be prepared in sufficient quantities.  
Fractionation of cells expressing these variants after 3 hrs is shown in the bottom panel 
of Figure 15. Interestingly, despite the increase in surface hydrophobicity the periplasmic 
band (P) for 4NLeu is fairly strong, indicating export still takes place and the changes to 
the surface of this variants is tolerated by the Tat proofreading system. The periplasmic 
band for 5NLeu and 6NLeu appears to be weaker, possibly indicating less efficient export. 
However, as with the previous surface alterations, an average for export efficiency of 
these variants can be seen in the final three bars in Figure 15, this highlights that creation 
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Figure 15: The Tat system tolerates significant surface hydrophobicity in scFvM. Top: 
surface hydrophobicity profiles for the N-terminal of scFvM. The unmodified variant is shown 
on the left with the progressive introduction of 4, 5 or 6 leucine residues to the right. Introduced 
leucine residues are indicated by red arrows and shown in solid yellow. Purple = non-
hydrophobic, yellow = hydrophobic. Bottom: Export assay of the hydrophobic variants 
compared to the unmodified scFvM. Molecular weight markers are shown on the left (in kDa) 
with precursor and mature scFvM indicated on the right.  
of a significantly hydrophobic patch is largely tolerated by the Tat proofreading system 
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Figure 16: Addition of a 26-residue disordered tail results in a complete block in export 
of scFvM by the Tat system. Immunoblotting to fractionation samples (as in Figure 9) from 
FXOWXUHV H[SUHVVLQJ WKH µWDLO¶ VF)Y0 YDULDQW EHDULQJ D -residue C-terminal extension. 
Equivalent number of cells were fractionated into C/M/P at 60, 75, 90 and 120 minutes post-
induction, with a total cell sample taken pre-induction (U) and at the 120 min time-point (TC). 
Molecular weight markers are shown on the left (in kDa).  
WDLO 
Export of scFvM by the Tat system is blocked by the addition of an XQVWUXFWXUHGµWDLO¶ 
This study has currently shown that the Tat proofreading mechanism is tolerant of 
changes to the surface charge of a heterologous substrate targeted for export via the Tat 
machinery. As a final part to this study we wanted to see if Tat proofreading could 
recognise an unfolded domain on a largely folded substrate. To this end we added 26 
residues, chosen at random, to the C-terminus of scFvM, creating scFvM-26tail 
(SNAIIIIITNKDProNSSSVDKLAAALE). Secondary structure modelling using the 
Phyre2 programme (Kelley et al 2015) indicates the core scFvM is unaffected by the 
addition of this tail while the tail itself is largely disordered (supplementary data Figure 
1). Export assays carried out over a 120 min time-course for scFvM-26tail is shown in 
Figure 16. It is clearly evident in this figure that this variant is not exported via the Tat 
system at any point throughout the 120 min induction period, showing Tat unambiguously 
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The study conducted in this chapter sought to more accurately identify the factors that 
dictate whether a substrate is transported or rejected by the Tat machinery. The 
predominant method by which this was addressed was by identification of any alteration 
to surface features were accepted or rejected by the Tat system. Secondly, tolerance for 
substrate conformational flexibility was also touched upon. Although the proofreading or 
transport mechanism is not understood in any detail at this stage, we assumed the Tat 
system may associate surface features, such as large areas of hydrophobicity, with an 
unfolded and therefore transport-incompetent state. We therefore began by manipulating 
the surface-exposed residues of a structurally characterised scFv in an attempt to induce 
rejection by the Tat machinery. Alongside this, due to recent evidence indicating the Tat 
machinery tolerates substrates that possess greater structural flexibility (Alanen et al 
2015, Stolle et al 2016), we also targeted scFvM to the Tat apparatus in the reduced and 
oxidised state as well as a version with a disordered C-WHUPLQDOµWDLO¶   
 
A range of scFvs have been efficiently exported via the Tat system in both oxidised 
(DeLisa et al 2003) and reduced states (Alanen et al 2015), we have found the export of 
scFvM to be almost totally dependent on the ability to be in the oxidised state (i.e. in the 
presence of CyDisCo or with bridge-forming Cys residues present). This indicates that 
the protein is more readily accepted by the Tat proofreading mechanism if intra-domain 
disulphides are formed. This is an interesting finding as scFvM is suitably folded (see 
biophysical data, Table 7, and protein A binding, Figure 12) and active (Edwardraja et al 
2010) when obtained from the cytoplasm in a reduced state. We interpret this to mean 
WKDW IRUPDWLRQ RI WKH GLVXOSKLGH ERQGV µORFNs¶ WKH VF)Y0 GRPDLQV LQ D PRUH ULJLG
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conformation while without these anchors (i.e. in the reduced state), scFvM is in a more 
dynamic state, possibly reminiscent of the molten globule and is thus deemed 
insufficiently folded by the Tat system, akin to for example TMAO reductase lacking a 
MGD cofactor. Additionally, reduced cysteine residues (SH HS) are more hydrophobic 
than their cysteine (S-S) counterparts (Nagano et al 1999), suggesting loss of these 
covalent linkages in scFvM results in increased flexibility, rather than destabilisation of 
the hydrophobic cores of the two domains. The entropic contribution of disulphide 
bridges to protein stabilisation has been well studied, and used as the basis for engineering 
stability (Zavodszky et al 2001). Cysteine and serine side-chains have very similar 
electrochemical properties, with the latter often used to test the effect disulphide bridges 
contribute to a protein. Therefore, the 10% export we observe in WT cells may well 
represent those molecules that happen to be in their most compact conformation when 
docking at the TatBC substrate-binding complex. Moreover, exchanging cysteine 
residues with serine, inhibiting bridge formation even in CyDisCo strains, produces a 
similar reduction on export efficiency. These data suggest that the folded state of a 
substrate is assessed by the Tat system with an ability to identify substrates in a highly 
dynamic state as opposed to aQ µXQIROGHG¶RUPLV-folded protein. Indeed, scFvM was 
specifically chosen and engineered for stable expression in the reducing environment of 
the E. coli cytoplasm (Edwardraja et al 2010, Austerberry et al 2017).  
 
The initial scFvM variants created in this study were designed to assess the capacity of 
Tat proofreading mechanism to sense surface charge of a substrate. In all but two of these 
variants substitutions were made in the same, specific area, creating a patch with a variety 
of different properties. In the first group of variants, up to three charge-neutral pairs (Lys-
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Glu) were introduced in the place of non-polar residues, however these variants are still 
exported with an efficiency comparable to the wild-type. 
 
The second group introduced a significant increase in either positive (Lys or Arg) or 
negative (Glu) charge in this same area through substitution of 5 uncharged residues by 
Lys, Glu or Arg. In the case of the Lys and Glu substitutions only a moderate decrease in 
export efficiency was observed (by ~30%). Evidently the Tat system can tolerate 
significant increases in the surface charge of a substrate, even when localised to a focused 
area. Interestingly, introduction of 5 Arg residues had a detrimental effect on export (by 
~80%) when localised to the same area, however replacement of 7 surface lysine residues 
with arginine only produced a moderate decrease in export efficiency, similar to that 
observed in 5Lys, 5Glu and 5R>K variants, suggesting it is not the specific side-chain for 
which Tat is intolerant but possibly the concentration of charge.   
 
The final group of variants created in this study were designed to give some idea of the 
level of hydrophobicity tolerated by the Tat system. Exposure of significant regions of 
hydrophobicity are hallmarks of unfolded or aggregation-prone proteins and we 
speculated that introduction of such a region may severely inhibit, or block export. 
Moreover, it was previously suggested that exposed hydrophobic domains blocked export 
for small, unstructured proteins (Richter et al 2007). In light of this it is interesting that 
creation of a substantial hydrophobic patch by substitution of uncharged residues with 4, 
5 or 6 leucine residues, has no significant effect on export efficiency. Modelling of these 
variants shows a significant patch of hydrophobicity is introduced at the N-terminal 
domain of scFvM. Given these data we conclude that a certain threshold of hydrophobic 
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character in a substrate is needed before rejection occurs, or that it is sensed in conjunction 
with other characteristics of Tat-targeted substrates, such as conformational flexibility.  
 
Finally, an unfolded domain was added to a folded substrate in the form of a disordered 
26-UHVLGXH µWDLO¶ ,Q FRQWUDVW WR WKH RWKHU YDULDQWV XVHG WR WHVW WKH 7DW SURRIUHDGLQJ
PHFKDQLVPLQWKLVVWXG\DGGLWLRQRIWKLVXQIROGHGµWDLO¶FRPSOHWHO\EORFNVH[SRUW7KLV
is in-line with the data obtained for the formation of intra-domain disulphide bridges, 
which have a stimulatory effect on export efficiency. These data represent various levels 
of an unfolded substrate, with a completely disordered domain (26tail variant) and a more 
dynamic, transiently-unfolded domain (scFvM lacking disulphide bridges) in an 
otherwise globular and relatively stable protein.  
 
For the structurally dynamic variants, scFvM 26tail and variants lacking disulphide 
bridges, the protein is not conILQHGWRDVSHFLILFVWUXFWXUHDQGLVDEOHWRµEUHDWKH¶It is 
beyond the scope of this study to more accurately identify the structural flexibility of 
scFvM and the variants generated, and further work could possibly do this in a more 
detailed manner, using a variety of substrates and utilising more sensitive techniques, for 






















Testing the proofreading capacity of the Tat system 
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In the previous chapter we have shown the Tat proofreading system is tolerant of 
significant alterations to the surface charge and increased hydrophobicity of a Tat-
targeted scFv. Conversely Tat proofreading has little tolerance for an scFv that lacks 
structural rigidity or contains a disordered C-terminal domain. Evidence abounds for the 
7DWV\VWHPV¶DELOLW\WRtransport heterologous proteins such as GFP (Thomas et al 2001), 
scFvs (Chapter 3, Matos et al 2014, Alanen et al 2015), interferons, VH domains (Alanen 
et al 2015) and FAB fragments (DeLisa et al 2003). Here we set out to test the export and 
proofreading capacity of the Tat system with a wholly artificial protein maquette, termed 
BT6.  
Maquettes were born of the desire to create proteins fit for purpose outside those found 
in QDWXUH'XHWRWKHµHYROXWLRQDU\EDJJDJH¶DFFXPXODWHGLQWKHDPLQRDFLGVHTXHQFHRI
natural enzymes, it is difficult to assign function to any one amino acid and derive any 
one function from a motif and thus achieve the desired outcome when importing a natural 
motif from an enzyme into a man-made construct (DeGrado et al 1989, Edelman and 
Gally 2001). More recently a new approach was undertaken that aimed to minimise 
complexity in the amino acid sequence while increasing engineering freedom. This was 
a bottom-XSDSSURDFKWKDWJHQHUDWHGKHSWDGUHSHDWVWRFUHDWHVROXEOHĮ-helical bundles. 
Within this framework the functionality of each amino acid is largely understood due to 
the small and simple nature of the maquette. Cofactor ligation sites were then inserted 
into this framework without mimicking natural enzyme motifs to create a protein with 
oxidoreductase capabilities e.g. electron transfer proteins (Shifman et al 1998). These 
ILUVWĮ-helical maquettes were helix-loop-helix homodimers tethered by a disulphide 
bridge. Due to their sequence symmetry, they are only able to bind single cofactors and 
perform relatively simple functions, such as proton coupling, electrochemical charge 
coupling and ligand exchange (Grosset et al 2001). This was overcome by removing the 
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disulphide tether and fusing the N-terminus of one unit to the C-terminal of another, 
generating a helix-loop-helix-loop-helix-loop-helix design (Lichtenstein et al 2012). The 
maquette used in this study, BT6, is of this single-chain design, developed by Farid et al 
2013. The sequence of BT6 is shown in Figure 17.A while a ribbon diagram and the heme 
b cofactor are shown in Figure 17.B. The BT6 four-helix bundle forms a water-excluding 
cavity where histidine residues form ligation sites for two heme b cofactors, producing 
an artificial protein resembling a b-type cytochrome. To be accepted by the Tat 
proofreading mechanism, BT6 needs to fold and acquire its heme cofactors in the 
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Figure 17: Primary amino acid sequence and structural features of maquette BT6. A: The 
signal peptide from TorA was fused to the N-terminal of BT6 (yellow) along with the first 
four amino acids of the mature TorA protein (green). The Gly/Ser linker between heptad 
repeats is in bold and underlined with heme b-binding histidine residues in orange and 
underlined. The C-terminal 6x histidine-tag is shown in brown. B: Left: Ribbon diagram of 
the holoprotein BT6 with two bound heme b PROHFXOHV Į-KHOL[   JROG ȕ-sheet = red, 
unstructured = grey and heme b = light green. Right: Cartoon diagram of BT6 bound to its co-
factor with an expanded section showing the heme b molecule. Images generated with CCP4 
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High-level overexpression of BT6 results in contamination of Periplasm with cytoplasmic 
protein 
Here we set out to test the ability of the Escherichia coli TatABC system to export a 
wholly artificial protein. This represents a challenge for the Tat system as, not only is 
BT6 a recombinant protein and thus not usually found in E. coli, it is wholly artificial 
protein and therefore not found in nature. The protein sequence shares no identity with 
natural proteins and avoids natural motifs. Given the expansion of synthetic biology and 
WKHJURZWKRIWKHµ¶SURWHLQWRROER[¶¶LQUHFHQW\HDUVLWZRXOGEHRILQWHUHVWWRNQRZWKH
capabilities of the Tat system with regards to entirely man-made proteins.  
The sequence for the signal peptide from E. coli TorA (trimethylamine-N-oxide 
reductase) along with the first 4 amino acids of the mature protein (highlighted in Figure 
17.A), were fused to the N-terminus of a heme b-binding maquette (denoted RRBT6h2), 
and expressed from plasmid pJExpress414, a high-copy vector with a T7 inducible 
promoter. In parallel to this, mutations to the TorA signal peptide that are commonly used 
to indicate protein is processed solely by the Tat system (and not by the Sec system) were 
LQWURGXFHG 7KHVH DUH DV IROORZV PXWDWLRQ RI WKH ILUVW $UJLQLQH LQ WKH µ55¶ PRWLI WR
Lysine (denoted KRBT6) which commonly has little effect on translocation in E. coli, 
and mutation of both Arginines to Lysine (denoted KKBT6) which leads to a block in 
export (Halbig et al 1999).  
Anti-His western blots to the C-terminal 6x His-tag of cultures expressing these plasmids 
and fractionated as described in section 2.3 are shown in Figure 18.A. Here it can be seen 
that induction with 0.5 mM IPTG results in protein being present in all three fractions 
(Cytoplasm, Membrane and Periplasm, C/M/P respectively) at the mature size with the 
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Figure 18: Overexpression of BT6 from the pJexpress414 plasmid causes contamination 
of the Periplasmic fraction. A: Immunoblot to the C-terminal 6x histidine-tag for C/M/P 
samples for expression of BT6h2 from the pJexpress414 plasmid. Functional TorA (RR) and 
a version blocked in transport (KK) are shown. B: Functional TorA signal peptide (RR) is 
shown alongside the two controls for non-functional signal peptide (KK) and BT6h2 lacking 
a signal peptide. Again precursor and mature bands are observed in all three (C/M/P) fractions. 
C: Coomassie-stained gel of the immunoblot shown in B. Bands corresponding to BT6h2 are 
easily the most abundant in each fraction. Molecular weight markers are shown on the left (in 
kDa) and precursor and mature BT6 indicated on the right. Precursor ± 21.8 kDa, mature ± 
17.11 kDa.  
wild-W\SHµ55¶VLJQDOSHSWLGH0XWDWLRQWRµ.5¶UHVXOWVLQDGHFUHDVHGDPRXQWRIH[SRUW
indicated by a less-intense band in the periplasPµ3¶ODQHDWPDWXUHVL]HDGGLWLRQDOO\
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However, there are periplasmic bands at precursor size for both KR and KK BT6h2 
products which indicates expression at this level causes leakage across the inner 
membrane of BT6. Indeed at mature size these are not processed by leader peptidase and 
thus likely do not cross the membrane via Sec/Tat.  
To further test whether expression level was the cause of contamination of the periplasmic 
fraction or if the Tat system simply could not recognise the synthetic BT6, the maquette 
was cloned into pJExpress414 without the signal peptide and expressed under the same 
conditions. In Figure 18.B a similar scenario to that in A is observed, namely both 
RRBT6h2 and KKBT6h2 are evident at mature size in the periplasm. Additionally, the 
final three lanes show BT6h2 with no signal peptide at all is found in all three fractions. 
The final panel (Figure 18.C) shows a Coomassie-stained gel of the blot in B. The 
different protein profiles of the C/M/P lanes indicate an efficient fractionation and no 
contamination across the fractions, indicating the mature BT6 present in the periplasmic 
fraction is due to some other factor, likely the very high expression level of protein from 
pJexpress414.    
 
Low-level expression of BT6 results in correct processing by the Tat system 
IPTG-inducible promoters are not always very tunable and thus we sought a different 
method to decrease the expression level of our BT6 constructs. We decided to clone the 
various constructs into the low copy-number plasmid pEXT22 which on average has 1 ± 
1.5 copies per cell (Dykxhoorn et al 1996) and also places the various BT6 constructs 
under the lower expression pTac promoter. Figure 19 shows fractionation of cells 
expressing RRBT6h2 and various controls from this vector. In Figure 19.A BT6h2 fused 
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Figure 19: Low-level expression of BT6h2 from the pEXT22 plasmid results in correct 
processing by the Tat system. A: C/M/P samples for BT6h2 fused to the TorA signal peptide 
(left) alongside the signal peptide control, KK, that is blocked in export (right). The middle 
lane shows a non-heme binding variant that is also blocked in export. B: Fractionation of 
BT6h2 with no signal peptide to act as further controls for correct processing by the Tat 
system. Molecular weight markers are shown on the left (in kDa) and mature BT6h2 is 
indicated on the right.  
processed to a mature size as evidenced by a band comigrating with the 17 kDa marker 
(16 981 Da). Successive lanes show RRBT6h2 is processed solely by the Tat system as 
KKBT6h2 is completely blocked for export, as is expression of the mature-size protein 
only (i.e. lacking the TorA signal peptide). The anti-His blot in Figure 19.B shows 
efficient export can be achieved for the KRBT6h2 construct whereas KKBT6h2 is 
blocked for export. BT6h2 lacking a signal peptide is also not exported to the periplasm. 
A lack of signal in the cytoplasm and membrane fractions we take to indicate almost all 
protein is exported due to the low levels of protein produced in this vector. A lack of 
signal in the non-exported constructs is likely due to degradation of non-exported Tat 
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The E. coli TatABC system rejects a synthetic protein in its apo form  
Ligation of heme into the interior of maquettes is known to increase the structural stability 
over the apo-form (Farid et al µWLJKWHQLQJ¶VWUXFWXUHDQGVLJQLILFDQWO\LQFUHDVLQJ
Tm. We used this characteristic to probe if Tat proofreading could identify a synthetic 
substrate that is not strictly folded i.e. a substrate that has obtained significant structure 
but lacks its cofactors. In our BT6 each heme is coordinated by two histidine residues and 
thus we created two versions of BT6: the first has a single His to Ala substitution such 
that only a single heme b ligates, denoted BT6h1. Second we substituted two His with 
Ala so that no hemes ligate, generating the apo-form denoted BT6h0. 
Each variant was expressed in the cytoplasm of E. coli BL21 (DE3) and purified via a 
Nickel affinity column. Figure 20 shows 1D proton NMR with purified BT6 variants 
(work carried out by George Sutherland at University of Sheffield), with and without 
bound heme. The broadening of the peaks observed when BT6h2 is bound to two heme 
cofactors is indicative of tertiary folding (panel A). The same phenomenon is observed 
with BT6h1 when the single heme is bound, although to a lesser degree (panel B). Finally, 
panel C shows no change in tertiary structure even in the presence of heme for the non-
heme-binding BT6h0. The top and middle panels in Figure 21 show overlays of all three 
variants without and with their maximum heme binding (left and right respectively).  
Cells expressing RRBT6h2, RRBT6h1 and RRBT6h0 were fractionated and anti-His 
blots to the cytoplasm/membrane/periplasm fractions are shown in the bottom panel of 
Figure 21. Here holo-BT6 (RRBT6h2) is exported and processed to the mature size as 
before, evidenced by the strong band in the periplasm. The single heme mutant 
(RRBT6h1), although exported and processed to mature size, has a distinctly weaker band 
than that of the wild-type indicating not all of the substrate is accepted as folded by the 
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Tat machinery. Finally, the apo-IRUPRI%755%7KZKLFKGRHVQ¶WELQGHLWKHUheme, 
is blocked for export. Precursor bands are evident in the cytoplasm (faintly) and 
membrane indicating BT6h0 is expressed and targeted correctly however is not accepted 
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Figure 20: 1D proton NMR for BT6 heme-binding variants. A: the broadening of the peaks 
in the absence and presence of heme b for BT6h2 indicates a tightening of tertiary structure 
(red and blue respectively). B: Peak broadening is slightly less pronounced for BT6h1, which 
is only able to bind a single heme b molecule (blue ± without heme, red = with heme). C: there 
is no change in the NMR trace in the absence or presence of heme b for the BT6h0 variant 




















BT6h2: blue = with heme, red = without heme 
BT6h1: red = with heme, blue = without heme 
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The apo form of BT6 can be exported by the Tat system only when linked after the mature 
form  
2XUQH[WVWHSLQWKLVVWXG\ZDVWRVHHLIZHFRXOGµµWULFN¶¶WKH7DWV\VWHPWRDFFHSWWKH
apo- form as folded and we thought it possible this could be accomplished if it was 
accompanied by a folded companion. Therefore, RRBT6h2-BT6h2, RRBT6h2-BT6h0 
and RRBT6h0-BT6h2 were created. These are the wild-type BT6 linked to the apo-BT6 
in various configurations via a 10 amino-acid linker and a C-terminal HA-tag, shown 
schematically in Figure 22.A.  
Early studies with maquettes attempted to increase the number and variety of cofactors 
DEOHWRELQGWRDVLQJOHPROHFXOHE\LQFUHDVLQJWKHQXPEHURIĮ-helices. Initially these 
were homodimers created by tethering two helix-loop-helix domains via a disulphide 
bond. The repetitive nature of the amino acid sequences in these constructs limited the 
number and variety of cofactors able to bind however. This problem was overcome by 
replacing the disulphide tether with a linker between helix 2 and 3. This tether is a 
variation of the flexible repetitive (Gly4/Ser)3 linker used in scFvs to link the two 
immunoglobulin domains and is composed of the sequence GGSGSGSGG. Our linker 
was composed of six histidine residues  
 
CHAP TER 4:  MAQUETTE BT6 
108 
 
Figure 21: Combined 1D proton NMR and export assays for the heme-binding BT6 
variants. A: Overlay for all variants in the absence of heme b. B: Overlay in the presence of 
hemeB. In the absence of heme b the traces are superimposable for each variant whereas in 
the presence of heme b peaks become more broad with increasing number of hemes able to 
bind, indicative of tighter tertiary structure (BT6h2 = blue, BT6h1 = green, BT6h0 = red). C: 
Export assay for each of the heme-binding variants. A decrease in export efficiency is 
observed for decreasing number of hemes able to bind. Molecular weight markers are shown 



















All variants, no-heme overlay: BT6h2 = blue, BT6h1 = 
green, BT6h0 = red.  
All variants, heme overlay: BT6h2 = blue, BT6h1 = green, 
BT6h0 = red.  
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and the first four amino acids of mature TorA, HHHHHHAQAA. This was deemed a 
suitable linker as the residues can form fairly flexible chains and the previously exported 
BT6 has both the N-terminal signal peptide (including AQAA) and the C-terminal six 
histidines (as a 6xHis-tag), neither of which hinder translocation compatibility.  
The single-chain form of maquette generated by incorporation of these linkers not only 
had greater freedom for variety of ligation sites DQGHQDEOHGWKHVHTXHQFHRIHDFKĮ-helix 
to be different, but it was also shown to still correctly fold (Farid et al 2013) into 4-helix 
bundles. Thus we can be reasonably certain our (helix-loop-helix-loop-helix-loop-helix)2 
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Figure 22: Schematic representations of linked BT6 variants. A: Dual heme-binding BT6 
was linked to the apo-BT6 (zero heme-binder) in various configurations. TorA signal peptide 
is yellow, with AxA cleavage site and first four amino acids of mature TorA (AQAA) shown. 
Pink indicates the mature protein. 10 amino acid linker and HA-tag are indicated in brown and 
black respectively. B: Schematic representation of predicted fold for linked BT6 constructs 














Due to the more acceptable expression level for our purposes, constructs were expressed 
from vector pEXT22 under the same conditions and fractionated. The top panel of Figure 
23 shows anti-HA blots of C/M/P fractions from cells expressing RR-BT6h2-BT6h2, RR-
BT6h2-BT6h0 and RR-BT6h0-BT6h2. Here it can be seen that the non-mutated form 
RRBT6h2-BT6h2 is exported by the Tat system, albeit not very efficiently, with the 
periplasmic (P) protein at the processed size of 34, 448 Da, just above the 32 kDa marker. 
The middle column is interesting because surprisingly, there is also mature-size protein 
evident in the periplasm for the non-mutated BT6 linked to apo-BT6 (RRBT6h2-BT6h0). 
$ 
% 
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Figure 23: BT6h0 can be exported by the Tat system when linked behind BT6h2. A linked 
BT6h2 is efficiently exported via the Tat system, while BT6h2 linked to BT6h0 is exported 
with reduced efficiency. Placing BT6h0 first results in a block in export (left, centre and 
middle lanes respectively). Constructs are shown schematically in Figure 22. Cultures were 
fractionated into C/M/P as in previous studies in this thesis. While the bottom panel shows 
expression in tat null strain. The lack of band in the periplasm (P lane) signifies these linked 
BT6 variants are still processed by the Tat system. Molecular weight markers are shown on 
the left (in kDa) with mature protein indicated on the right.  
Whether this is due to the mature form stabilising the apo-form or if the Tat system only 
proofreads upon initial docking of substrate and not throughout translocation, is beyond 
the scope of this study. Evidence for the latter scenario is shown in the final column 
however, where placing apo-BT6 first results in rejection by the Tat proofreading 
mechanism as there is no band evident in the periplasmic fraction. 
The bottom panel in Figure 23 shows a control to ensure the linked BT6 variants are 
exported exclusively by the Tat system by expression of the constructs in ǻWDW$%&'(
cells. As expected, no protein is present in the periplasm lane, indicating protein is indeed 
processed by the Tat system alone.  
TorA KR versions of the linked BT6 variants were also created to see if a lack of the dual 
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This study set out to analyse the capacity of the Tat system to export a wholly synthetic 
protein maquette, one that is completely designed de novo, to the periplasm in E. coli. In 
the initial stage of this study, BT6 was expressed in vast quantities from plasmid 
pJexpress414. Although expression at this level resulted in some processing by the Tat 
system, as shown by a mature-size band in the periplasm fraction, the vast majority of 
protein was found at precursor size, or in the periplasm at mature size even when no 
targeting signal was present. There are two scenarios that could cause this effect: 1) BT6 
interacts with the membrane and destabilises it. As maquettes are attempts to mimic 
naturally membrane-associated proteins, such as those of the electron transport chain, this 
is a high possibility. 2) cytoplasmic contamination of the periplasmic fraction during 
fractionation could occur. This scenario cannot be ruled out, but is unlikely given the 
protein profiles of cytoplasm, membrane and periplasm fractions are different and do not 
share banding patterns (Figure 18.C). Additionally, a combination of these scenarios 
cannot be ruled out - where membrane destabilisation by membrane-associated BT6 leads 
to cytoplasmic leakage during fractionation. Nevertheless we attempted to counter these 
issues by expressing the Tat-targeted BT6 from a lower-expression plasmid. These 
experiments show the Tat system can indeed identify the de novo designed BT6 and 
transport it to the E. coli SHULSODVP0RUHRYHUPXWDWLRQVWR WKHµ55¶PRWLI LQ WKH7DW
signal peptide indicate BT6 is transported solely by the Tat pathway.  
In the next stage of this study we took advantage of the effect on BT6 structure for binding 
to the heme b cofactor, and we thus substituted histidine ligation sites with alanine to 
block binding of a single or both heme b cofactors. NMR has previously shown the 
increase in tertiary structure exhibited by BT6 in a heme-free, single-heme and bis-heme 
states (Farid et al 2013 and Figure 20 A, B & C and Figure 21: Top panel), and we thought 
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this an excellent opportunity to test the Tat proofreading system, not only in general but 
also on a protein not found in nature. In the absence of heme i.e. when BT6 has the most 
structural flexibility, the Tat proofreading system rejects the BT6 substrate for export. 
Moreover, as heme b ligation sites are increased from zero to two the suitability for Tat-
mediated export also increases. These data suggest that as BT6 loses structural flexibility 
upon increasing number of cofactor binding it becomes more acceptable to the Tat 
proofreading mechanism, similar to the scenario observed when scFvM is expressed in 
cells with an oxidising cytoplasm and is able to form disulphide bonds (chapter 3). In this 
scenario, a more flexible substrate would interact with the Tat machinery upon initial 
binding, which would in turn preclude transport of substrate across the membrane.  
In the final section of this study we sought to address whether we could get the Tat 
proofreading mechanism to accept a substrate with a structurally flexible domain. To this 
end we joined the bis-heme binding BT6h2 to the heme-free BT6h0 in various 
configurations via a short, 10 amino acid, linker. The data obtained show that, perhaps 
surprisingly, the more structurally flexible BT6h0 is accepted for translocation via the Tat 
system only when linked behind a bis-heme-binding (i.e. more structurally ridgid) BT6h2. 
This scenario suggests that proofreading of substrate takes place only upon initial 
interaction of substrate with the Tat machinery, likely after signal peptide binding to 
TatBC but before translocation, and once accepted by the Tat proofreading mechanism, 
substrate is committed to export. The data presented here along with that observed by 
others (Cline et al 2007, Lindenstraub et al 2009, Taubert et al 2014) would make sense 
LIVXFKDVFHQDULRZDVWKHFDVHDQGSURRIUHDGLQJLVQ¶WDQRQJRLQJSURFHVVWKURXJKRXWWKH
translocation process. This mechanism would also explain the delay between substrate 
binding at the TatBC complex and translocation across the membrane, both processes that 
occur on a timescale of seconds. Further work would need to look at the exact structure 
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or folded state and heme-occupancy of the double BT6 maquettes presented in this study 
in order to more closely identify characteristics that Tat proofreading system identifies.  
This study has not only provided interesting insights into the proofreading by the Tat 
machinery but has also shown the system is amenable to the translocation of protein 
substrates never before seen in nature to the periplasm of E. coli. This is convenient as it 
could prove useful for downstream processes (e.g. purification) of de novo designed 
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The market value of all licenced recombinant biotheraputic proteins has easily surpassed 
a hundred-billion dollars per year. 68% of recombinant proteins are derived from 
microbial platforms with purification from Escherichia coli the most common non-
mammalian system (Walsh et al 2014). Expression takes place in the cytoplasm, at which 
point several options are available: purification from the cytoplasm, refolding from 
inclusion bodies, export to and purification from the periplasm via the General Secretory 
(Sec) pathway or, in rare cases, secretion to the culture medium via OsmY fusions. 
Secretion to the culture medium has significant benefits as it would enable continuous 
growth while siphoning off product, decreasing time and costs. However, this method is 
still very much in its infancy (Georgiou and Segatori 2005).  Secretion to the periplasm 
is relatively simple, only requiring an N-terminal signal peptide and associated protein-
conducting channel (section 1.1 and 1.2 and reviewed in Yuan et al 2010). Periplasmic 
expression enables a simplified purification procedure by selectively rupturing the 
bacterial outer membrane (Pierce et al 1997). This minimises the number and abundance 
of contaminating proteins, DNA and cellular debris (Balasundaram et al 2009). As 
discussed in section 1.2, the Sec pathway requires proteins to be in an unfolded state for 
translocation. As an alternative method of localising proteins to the periplasm, the Tat 
pathway can transport fully folded proteins. A unique feature of the Tat pathway though 
is its in-built proofreading mechanism that can detect structurally dynamic substrates and 
reject them for export (chapter 3 & 4), an important point for those recombinant proteins 
requiring disulphide bond formation (e.g. mAbs and hormones) or cofactor insertion. This 
proofreading capability could indicate a purer, more homologous product is present in the 
periplasm and thus a greater yield upon purification. In this chapter, we have sought to 
address this issue by targeting a model recombinant biotheraputic ± human Growth 
Hormone (hGH) ± for export to the periplasm of Escherichia coli via either the Sec or 
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Tat pathway. hGH was then purified from the periplasm by Ni IMAC before being subject 




The Sec system is more metabolically draining that the Tat system 
In this study the aim was to highlight any structural differences between proteins 
produced and purified from the periplasm when targeted to either the Sec or Tat pathways. 
To this end we chose a well characterised model protein with biotheraputic relevance ± 
human Growth Hormone (hGH). We created two identical plasmids that transcribed hGH 
and placed either a Sec or Tat signal peptide at the N-terminal. The Sec signal peptide 
was taken from the Outer membrane protein (OmpA-hGH), while the Tat signal peptide 
was taken from TMAO reductase (TorA-hGH). These are the traditional signal peptides 
used for targeting proteins to the Sec and Tat pathways respectively.  
Figure 24 shows growth curves for E. coli BL21(DE3) transformed with either the Sec or 
Tat plasmid (blue and orange respectively) from inoculation, through induction with 0.5 
mM IPTG (3 hrs, red arrow) and on to fractionation 3 hrs post-induction (6 hrs growth 
total, green arrow). Here it can be seen that although cultures harbouring Sec or Tat 
plasmids have the same overall growth profile, cultures expressing TorA-hGH reach 
significantly higher OD600 over this period (OmpA: 0.678, TorA: 1.965 average of six 
curves). Prior to induction, growth is similar for cultures with either plasmid. However, 
post-induction growth for cultures expressing OmpA-hGH decreases dramatically, 
appearing to almost enter stationary phase. Conversely, cultures expressing TorA-hGH 
continue in exponential phase until 2½ hrs post-induction. This becomes clearer when 
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Figure 24:  Cells grow more slowly over a 3 hr period when rhGH is targeted to the Sec 
pathway over the Tat pathway. Growth curves for cultures harbouring plasmids encoding 
human growth Hormone (hGH) targeted to the periplasm via either the Sec (OmpA) or Tat 
(TorA) pathway. Induction with 0.5 mM IPTG was at 3 hrs (red arrow) and fractionation was 
carried out at 30 min post-induction and 3 hr post-induction (green arrows). Each curve was 
generated from the average of 6 separate cultures. Maximum OD600 were: OmpA 0.678, TorA 
1.965 and Empty 2.295.  
growth curves are combined in Figure 25.A and compared to an empty strain (maximum 
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Figure 25: hGH targeted to the periplasm via the Sec pathway is immediately available 
whereas Tat-targeted protein builds up over a longer time period. A: The combined 
growth curves more clearly show the inhibitory effect on cell growth from targeting hGH to 
the periplasm via the Sec pathway. B: Samples 30 minutes post-induction are shown in the 
left three columns (C/M/P) and after 3 hrs in the right. Fainter bands are observed for 30 
minutes post-induction for Tat-targeted protein. Molecular weight markers are shown on the 
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Figure 26: Targeting hGH to the periplasm via the Tat pathway results in a larger 
insoluble fraction. After 3 hrs induction, cultures were fractioned into C/M/P and Insoluble 
fraction (I). There is a large amount of insoluble hGH when targeted to the Tat pathway 
(Tor$/HIW&RRPDVVLHVWDLQHGJHOWKHSUHGRPLQDQWEDQGLQ7RU$µ,¶ODQHLVK*+5LJKW
Immunoblot of the gel shown on the left.  
Fractionations of culture into cytoplasm, membrane and periplasm at time points 30 min 
post-induction and 3 hr post-induction are shown in Figure 25.B. Here we see that after 
30 minutes induction, OmpA-hGH has already built up significantly across all three 
fractions (left three columns) and remains consistent up to 3 hrs (right three columns). 
Whereas TorA-hGH is barely evident 30 minutes after induction and a consistent increase 
in protein happens over the 3 hrs of induction. After 3hrs induction, cells were 
fractionated into cytoplasm, membrane, periplasm and insoluble (I) fractions in an 
attempt to identify any bottlenecks or saturation of the pathway. Figure 26 reveals there 
is a marginal amount of hGH present in the insoluble fraction for Sec-targeted protein 
(equivalent to the amount in other fractions). For protein targeted to the Tat-pathway 
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Sec and Tat transported human Growth Hormone are equally folded 
Previous chapters have shown the Tat system more readily exports proteins that are in a 
less dynamic state (i.e. more tightly folded), therefore we thought it pertinent to assess 
the homogeneity and folding characteristics of Sec- and Tat-targeted hGH. We developed 
the hypothesis that as the Tat system more efficiently exports structurally rigid proteins, 
protein UHDFKLQJWKHSHULSODVPYLDWKLVURXWHZRXOGKDYHDµWLJKWHU¶VWUXFWXUH 
First, hGH was purified from the periplasm after 3 hrs induction for OmpA- and TorA-
hGH by Nickel IMAC (section 2.4.1). The protein elutes immediately within the first 5 
fractions, to a pure degree for protein exported via either pathway as shown by the 
absence of contaminating band in the Coomassie stained gel (left, Figure 27). Some TorA-
hGH is lost in the wash fraction as evidenced by a band in the western blots (middle and 
right panels). Fractions containing pure protein were pooled (E1 ± E5 in both cases) and 
were dialysed overnight into sodium phosphate buffer (section 2.4.3). The following day 
dialysed sample was spun at 4000 rpm in VIVASPIN 20 10, 000 MWCO spin columns 
(Sartorius, Gottingen, Germany) to a volume of 250 µL. The concentration determined 
by A280 and a calculated molar extinction coefficient of 17 670 M-1 (Expasy Protparam) 
as 2.1 mg/mL and 1.3 mg/mL for OmpA- and TorA-hGH respectively (Figure 28), and 
verified by NanoDrop.  
One-dimensional proton (1H) NMR spectroscopy was used to assess the tertiary structure 























Figure 27: Ni IMAC purification of hGH from the periplasm. The top row shows purification from the periplasm 
for hGH via the General secretory pathway, while Tat hGH is shown in the bottom row. Left: Coomassie stained gel 
of the periplasm (P), flow through (FT), Wash (W) and elution fractions (E(n)). Pooled fractions are indicated. Note 
the lack of contaminating bands. Middle and Right: western immune blot to the C-terminal 6x histidine tag (middle) 
or anti-hGH (right).  
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Figure 28: Purified hGH. Concentration of hGH in each sample was calculated by A280 and a molar extinction 
coefficient of 17 670 M-1 as 2.1 mg/mL and 1.3 mg/mL for Sec secreted and Tat secreted respectively.  
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Figure 29: Full spectrum proton NMR resonances for purified hGH processed by either 
the Sec or Tat pathway. Overlay of the Sec-hGH (red) and Tat-hGH (blue) full spectrum (the 
large peaks at 1.2 ppm and 3.6 ppm are likely due to contaminating ethanol, asterisked (Fulmer 
et al 2010)). The HDO signal is suppressed with a double forward slash (//).  NMR contributed 
by Dr Gary Thompson at the University of Kent.  
Sec- and Tat-processed hGH were dissolved in a mixture of 5% D2O/95%H2O buffer 
containing 50 mM sodium phosphate, 150 mM sodium chloride at pH 7.4. These were 
analysed after extensive dialysis to reduce effects due to any systematic differences in 
sample preparation. Spectra were acquired at 298 K using a double pulse field gradient 
spin echo sequence (DPFGSE) to suppress water. Data were acquired on a Bruker 
Advance III spectrometer operating at 600 MHz with a He cooled cryogenic 
probe.  Spectra were measured using 2048 complex data points over a sweep width of 
9615 Hz using 1024 scans with an inter-scan relaxation delay of 1s. These data were 
processed and analysed using Topspin (Bruker) an exponential function of 8 Hz was 
applied to improve signal to noise, with zero filling being carried out to 8192 data points. 
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Both Sec- (red) and Tat-hGH (blue) samples have spectra of a well-folded protein 
(Figure 29), as indicated by the broad dispersion of signal in the amide (Figure 30.B) 
and aromatic regions of the spectrum. Ring shifted methyl peaks, attributable to 
stacking of the methyl groups on aromatic rings in the core of a protein, are also 
observed (Kwan et al 2011) and these align between samples (Figure 30.A, indicated by 
black arrows). Overall the spectra are largely similar and subtle differences may be due 
to inconsistent salt concentrations between samples. The NMR work was carried out by 
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Figure 30:  Expansion of the methyl and aromatic regions for 1H NMR spectra for Sec 
and Tat processed hGH. A: Expansion of the methyl region with Sec (red) and Tat (blue) 
hGH overlaid. The black arrows indicate the ring-shifted methyl peaks indicative of a folded 
protein. The alignment of these peaks indicate protein processed via either pathway has the 
same fold. B: Expansion and overlay of the amide region. NMR contributed by Dr Gary 



























The recombinant production of proteins in a bacterial host is the predominant platform 
for production of biotheraputics. Typically, these proteins are refolded from inclusion 
bodies or released from the periplasm, the latter being the less time-consuming and 
intense approach. Here we set out to compare the current mechanism for recombinant 
protein export to the periplasm via the Sec pathway with an alternative method ± targeting 
to and export by the Tat pathway. To this end we secreted recombinant human Growth 
Hormone (rhGH) to the periplasm of E. coli via either pathway. While cultures expressing 
TorA-hGH grew to higher ODs, the amount of protein produced after 3 hrs was the same 
for both systems. Furthermore, targeting of hGH to the Tat system, resulted in a larger 
amount of insoluble product and this is likely due to the slow rate of export by the Tat 
system. Previous reports have shown if substrates are not committed to export within a 
certain time, they are Tat-dependently degraded. Purification and structural analysis by 
CD and Proton NMR of the products reveals that periplasmic rhGH is structurally similar 
and folded to an equal degree. The data also suggest the hGH produced by either means 
here are equivalent to a biopharmaceutical-grade hGH standard.   
The Tat system is well known for employing a proofreading mechanism and previous 
chapters in this study have shown an increase in export efficiency for those substrates that 
are less structurally dynamic. The initial premise that export to the periplasm via the Tat 
pathway would produce a more structurally ridgid protein was not proven, in fact the 
proteins are of an equal quality. However, it has been shown that hGH is active and folded 
without formation of disulphide bonds (Bewley et al 1969, Youngman et al 1995) and 
previous studies with the Tat system have shown disulphide bonds are not necessary prior 
to export for hGH (Alanen et al 2015). Therefore, the cytoplasmic disulphide-forming 
system, CyDisCo, was not used in this chapter. When the Tat system is combined with 
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the CyDisCo components, a more structurally compact product may arise and this would 
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Previous chapters have shown that the Tat system is capable of exporting two 
heterologous proteins; an scFv and a completely synthetic hemeB-binding maquette 
termed BT6. Moreover, the Tat proofreading mechanism was shown to be tolerant of 
significant variances in surface charge, both positive and negative, and hydrophobicity, 
while also being able to identify and reject substrates with disordered domains or lacking 
a cofactor. Given these data we assume the Tat proofreading mechanism favours rejection 
of substrate proteins based on conformational flexibility. For example, an scFv lacking 
native disulphide bonds is exported with circa 10-fold less efficiency than the oxidised 
form (chapter 3). Similarly, BT6 is only exported when heme B cofactors are able to bind 
imparting a significant increase on structural rigidity (chapter 4). In this chapter we 
wanted to address the proofreading process in the Tat components and attempt to restore 
export of these export-incompatible substrates.  
The E. coli Tat system is composed of the three integral membrane proteins TatA, TatB 
and TatC (section 1.3 and reviewed in Berks 2015). TatA and TatB are members of the 
same family of proteins that comprise a short N-terminal domain, a TM domain, a hinge 
region, an amphipathic helix and finally a variable-length, unstructured C-terminal 
domain (section 1.3.1.1 and 1.3.1.2). Several studies have sought to determine the core 
domains and key residues necessary in TatA-family proteins for functional translocation 
by the Tat system (Lee et al 2002, Barrett et al 2003, Hicks et al 2005, Barnette et al 
2008, Warren et al 2009, Maldonado et al 2011). Mutagenesis studies identified that 
while the Gly at position 21 in E. coli TatA and TatB is conserved, it is not essential for 
function and substitution with equally flexible residues (e.g. alanine) results in a slightly 
reduced, but still functional translocase (Barrett et al 2003). Additionally, altering the 
charged nature, but maintaining the hydrophilicity, of the cytoplasmic face of the TatA 
APH has little effect on translocase functionality, whereas substitutions within the 
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hydrophobic face generally reduce Tat functionality to minimal levels (Barrett et al 2003, 
Hicks et al 2005). The moderate importance of these residues is highlighted by the 
perhaps interesting phenomenon that certain substitutions block export when the Tat 
components are expressed at wild-type levels (i.e. from the chromosome) whereas 
overexpression from a plasmid leads to reduced, but still functional, translocase activity 
(Warren et al 2009).  
TatA is 89 amino acids while TatB is 171. Several truncation studies in E. coli all agree 
that truncation of TatA by up to 40 amino acids and TatB by up to 130 amino acids 
maintains functional export of proteins utilising the Tat pathway (Lee et al 2002, Warren 
et al 2009). The case in TatB is a little more complex as wild-type levels of export were 
observed for truncations up to 30 amino acids whereas truncations between 40 and 130 
aas maintain a reduced level of transport activity (Lee et al 2002). Interestingly, these 
truncations in TatA and TatB leave a minimal functional protein composed of the N-
terminal periplasmic domain, the TM domain and the APH. Indeed, in TatA highly acidic 
residues at positions 45, 46 and 47 (E. coli QXPEHULQJ GHQRWHG DQ µ¶DFLGLF PRWLI¶¶
immediately following the APH were shown to be important for a functional Tat 
translocase at both wild-type and high expression levels (Warren et al 2009), possibly 
due to destabilisation of the TatA pore-forming complex (section 1.3.4).  Moreover, these 
truncated TatA and TatB proteins are able to complement tatAE, tatB and tatAEB deletion 
strains (Lee et al 2002).  
The results of these studies have led to some confusion as to the purpose of the, largely 
unstructured, C-terminal regions of the TatA-like components, especially when it is taken 
into consideration that these proteins from the majority of organisms in which a Tat 
system is present possess this unstructured C-WHUPLQDOµGRPDLQ¶,IWKLVUHJLRQZDVQRW
essential, surely selection pressure would favour Tat-components of a more truncated 
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nature. Therefore, in this chapter we have laid the groundwork for probing the Tat 




Truncation of TatA by up to 40 amino acids is able to complement the ǻWDW$%&'(
phenotype 
We first constructed C-terminal truncations in the TatA subunit of the Escherichia coli 
TatABC complex by substitution of residue-encoding codons with STOP codons (TAA 
or TAG) to generate TatA-20, TatA-30, TatA-40 and TatA-45 amino acids in plasmid 
pWM-Tat0 which encodes the E. coli TatABC components followed by a Strep-II tag at 
the C-terminal of TatC and is arabinose inducible. The Strep-II tag was necessary to 
confirm expression of all three Tat components (as each subunit has its promoter within 
the preceding gene), and previous studies have shown a C-terminal Strep-II tag in this 
position does not inhibit Tat function (Warren et al 2009). Plasmids were induced with 
0.05 mM arabinose and expressed for 3 hrs before an equivalent number of cells were 
fractionated into cytoplasm, membrane and periplasm and immunoblotting to the Strep-
II tag, shown in Figure 31. A band is apparent at the appropriate size for TatC (28.9 kDa) 
indicating transcription of the entire TatABC codon is occurring. Interestingly, despite an 
equivalent number of cells, band intensity decreases for increasing truncation length.  
 
Inactivation of the Escherichia coli Tat pathway through deletion of tatAE, tatB, tatC or 
tatABCDE genes show defects in cell division. This manifests as formation of cell-chains 
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Figure 31: Expression of truncated TatA from the arabinose-inducible Tat0 plasmid. 
Wild-type and truncated TatA variants were expressed in a tat null strain. After 3 hrs induction 
equivalent cell densities were fractionated into C/M/P and immunoblotted to the C-terminal 
StrepII tag. Top: ǻWDW$%&'( strain with no plasmid is run alongside Tat0 expressing wild-
type TatABC and TatA missing 20 or 30 aas from the C-terminal. Bottom: ǻWDW$%&'( and 
wild-type strain with no plasmid is shown against the non-functional TatA missing 45 aas. 
Plasmids were induced with 0.1 mM arabinose.   
up to 10 cells long (Stanley et al 2001), which are visible under a light microscope. This 
chain formation is likely due to the inability to transport the native Tat-substrates AmiA 
and AmiC to the periplasm. AmiA, AmiB and AmiC are cell wall amidases involved in 











during cell division. While AmiB is a Sec substrate, it requires overexpression to 
complement the ǻWDW$%&'( phenotype (Ize et al 2003), and thus at native expression 
levels ǻWDW$%&'( strains have a filamentous phenotype.  
Plasmid encoding either wild-type TatABC, TatA-20, TatA-30, TatA-40 or TatA-45 were 
transformed into MC4100 ǻWDW$%&'( strain and grown aerobically for 18 hrs at 30°C. 
The pWM-Tat0 plasmid is a pLysSBAD derivative and thus is leaky, therefore no inducer 
was used in an attempt to mimic wild-type TatABC expression levels (Warren et al 2009). 
Į-Strep 
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Images representative of cultures expressing these plasmids are shown in Figure 32 
alongside ǻWDW$%&'( and wild-type MC4100 controls. Here the cell-chain phenotype 
characteristic of ǻWDW$%&'( strains is immediately obvious, with restoration of the wild-
type phenotype observed upon expression of full-length TatABC (top row right and 
second row left respectively). A phenotype like that of the ǻWDW$%&'( strain is observed 
for TatA-45 with chains of up to 10 cells, consistent with a Tat system that is non-
functional. Interestingly, a partial phenotype is observed for TatA-20, TatA-30 and TatA-
40 which show progressively longer cell-chains, similar to that observed for ǻWDW$ but not 
ǻWDW( or ǻWDW$( strains (i.e. in strains with functional tatBCDE) (Stanley et al 2001).  
To further test the functionality of the Tat systems with truncated TatA we screened for 
growth on LB agar plates supplemented with 2% SDS. Due to the cell separation defects, 
inherent in E. coli strains lacking a functional Tat system they are extremely sensitive to 
hydrophobic antibiotics (such as ampicillin) and the anionic detergent SDS (Stanley et al 
2001, Ize et al 2003). Thus E. coli strains with a functional Tat system are able to grow 
on LB plates supplemented with up 4% SDS, while those with defective Tat apparatus 
are unable to survive when as little as 2% SDS is present (Ize et al 2003). For this reason, 
MC4100 ǻWDW$%&'( strains transformed with plasmids encoding TatABC, TatA-20, 
TatA-30, TatA-40 or TatA-45 were grown on LB agar plates supplemented with 2% SDS 
and 0.05 mM arabinose to induce Tat components and incubated at 37°C for 24 hrs. The 
left image in Figure 33 shows growth of ǻWDW$%&'( expressing TatABC, TatA-20, TatA-
30, TatA-40 or TatA-45 on 2% SDS plates. Colony growth of TatA-20 and TatA-30 is 
comparable to the wild-type and ǻWDW$%&'( expressing full-length TatABC, whereas 
expression of TatA-40 only leads to partial growth and TatA-45 inhibits growth, 
mimicking the phenotype of ǻWDW$%&'(. These results reflect those observed for the 
filamentous phenotype, although it is surprising perhaps that TatA-20 and TatA-30 
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Figure 32: Truncated TatA does not complement the filamentous phenotype of 
ǻWDW$%&'( cells. Top: microscope images of wild-type and ǻWDW$%&'( cells. Middle: 
restoration of the wild-type phenotype in ǻWDW$%&'( cells through expression of TatABC 
from the Tat0 plasmid and plasmid encoding TatABC with TatA truncated by 20aas. Bottom: 
ǻWDW$%&'( cells expressing truncated TatA by 30 and 40aas does not complement the 
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Figure 33: Growth of truncated TatA or TatB on LB agar plates supplemented with 2% 
SDS and 0.05 mM arabinose. Truncated TatA and TatB components enable growth on SDS 
plates except those that result in non-functional translocase i.e. TatA-45 and TatB-130. Left 
image, clockwise from top: ǻWDW$%&'( expressing TatABC, TatA-20, TatA-30, TatA-40 
TatA-45 from pWM-Tat0. Right image, clockwise from top: ǻWDW$%&'( expressing TatB-
30, TatB-50, TatB-75, TatB-130, TatB-20 from pWM-Tat0.  
Truncation of TatB by up to 130 amino acids is able to complement the ǻWDW$%&'(
phenotype 
After assessing the impact of a truncated TatA component, we wanted to determine the 
impact of a truncated TatB component. Therefore, we constructed truncations in the TatB 
subunit of TatABC in the same manner as in the previous section for TatA ± by 
substitution with STOP codons (TAA or TAG). TatB-20, TatB-30, TatB-50, TatB-75 and 
TatB-130 in pWM-Tat0 were thus generated. ǻWDW$%&'( cultures expressing these 
constructs were fractionated (C/M/P) and samples blotted against the Strep-II tag (A & B 
in Figure 34) A band at ~28 kDa is observed in the membrane fraction, the correct size 
for TatC, indicating successful induction of the plasmids. The intensity of the band 
appears greatly reduced in comparison to that of the full-length Tat components (TatABC 
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It was also possible to carry out anti-TatA blots for these constructs, a feat not possible 
in the previous section as the truncation of TatA interfered with binding of the TatA 
antibody (see TatA-45 lane, Figure 34.C). Western blots using antibodies generated to 
TatA were carried out for fractionation of cultures expressing the TatB truncation 
plasmids. These are shown in Figure 34 C&D. Here, low levels of TatA are observed in 
cultures of wild-type cells (MC4100 lane), with large amounts of TatA present in those 
cultures expressing Tat components from the modified pWM-Tat0 plasmids (ABC, A-
45, B-20, B-30, B-50, B-75 and B-130 lanes). To act as negative controls, fractionation 
of ǻWDW$%&'( cells and TatA-45 expressing cells are loaded. No TatA is blotted in either 
of these cultures.  
Blotting to TatA and the Strep-II tag of TatC give us significant confidence that all three 
components (TatA, TatB and TatC) are being translated, and help to assure the validity 
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Figure 34: anti-StrepII (A&B) and anti-TatA (C&D) immunoblot for expression of 
truncated TatB from the Tat0 plasmid. Wild-type and truncated TatB variants were 
expressed in a tat null strain as in Figure 30. A: wild-type MC4100 cells with no plasmid 
then ǻWDW$%&'( expressing wild-type ABC, non-functional TatA and TatB missing 20 aas 
(left to right). B: empty ǻWDW$%&'( cells and the same expressing TatB truncated by 50, 75 
or 130 aas from the C-terminal. C & D are the same layout as A and B respectively. The lack 
of signal in the TatA-45 lane indicates binding of antibody is likely in the C-terminal domain 
and thus not suitable for use in the TatA truncation studies. TatA is running as a dimer ~ 18 
kDa. Molcular weight markers are shown on the left (in kDa) and TatC/TatA is indicated on 
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Once the expression of truncated TatB was verified we observed the phenotype of 
ǻWDW$%&'( cells expressing these constructs under the microscope and growth upon 2% 
SDS plates. Figure 35 shows cultures at 400x magnification. The truncated TatB variants 
all complement the tat null chain-forming phenotype (Figure 35, top left panel), except 
the non-functional TatB-130. An interesting phenomenon when taking into consideration 
expression of the TatA truncations still formed cell-chains (Figure 32).  The plates in the 
right-hand panel of Figure 33 show growth of TatB truncations on 2% SDS plates. All 
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Figure 35: Truncated TatB complements the filamentous phenotype. Top: images of 
ǻWDW$%&'( expressing TatA-45 and TatB-20. TatA-45 encodes a non-functional Tat system 
and has a filamentous phenotype whereas TatB-20 has the wild-type phenotype of individual 
cells. Middle: TaB-30 and TatB-50. Bottom: TatB-75 and the non-functional TatB-130. Scale 
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Whereas in previous chapters we have utilised substrates targeted to the Tat system in 
attempts to more accurately identify what is sensed by the proofreading mechanism in 
order to be rejected for export, here we have attempted to ascertain the region in the Tat 
components themselves that are responsible for proofreading taking place. Namely in the 
TatA-like components of E. coli TatABC system, TatA and TatB. 
Building on previous work by our lab and others that indicated the unstructured tail of 
these components was not necessary for Tat functionality with native substrates, we 
thought this region could interact with substrate upon docking or translocation initiation 
and serve a role in proofreading. Therefore, we constructed multiple versions of an E. coli 
TatABC plasmid where TatA or TatB had blocks of residues removed from the C-
terminal. We have shown through a variety of assays these are expressable in E. coli, 
although possibly to a lesser degree than full-length TatABC based on the decrease in 
signal for anti-StrepII blots.  
Expression of full-length TatABC complements a chain-forming phenotype of a 
ǻWDW$%&'(strain. This is well known. We show however, that upon truncation of TatA 
or TatB by up to 40 or 130 aas respectively only partial complementation of this 
phenotype occurs. This could indicate limited Tat functionality as the cell wall amidases 
AmiA and AmiC, which are native Tat substrates, are not consistently being secreted to 
the periplasm. An interesting prospect as this could be due to one, or a combination, of 
two things: 1) truncation of TatA or TatB, while not abolishing Tat export, may reduce 
functionality. Previous studies have partially taken this into account and this may indeed 
be the case for truncations in TatB. 2) A loss or interruption of the proofreading 
mechanism, allowing mis-folded and therefore inactive amidases to be translocated.  
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Susceptibility to low levels of SDS is a hallmark of the ǻWDW$%&'(strain and Figure 33 
shows these cannot grow on SDS supplemented plates. Restoration of growth on these 
plates is achieved through expression of full-length TatABC. Perhaps in contrast to 
complementation of the filamentous phenotype, truncation of TatA or TatB also enables 
growth on 2% SDS supplemented agar plates, at least until large sections from the C-
terminal have been removed (40 aas and 130 aas for TatA and TatB respectively). This 
could indicate that while the Tat machinery is not functioning at 100% (as they still have 
a filamentous phenotype), it is still enough to stabilise the membrane, rendering cells 
more resistant to detergent.  
Here we have laid the groundwork for attributing a functionality to the largely 
unstructured C-terminal domains of the TatA and TatB components of the E. coli TatABC 
machinery. While the findings presented in this chapter are interesting and hint at a role 
in either proofreading or complex stability for the C-terminal domain of these smaller Tat 
subunits, unfortunately time-constraints meant it was not possible to further asses these 
variants with more dynamic, folding deficient substrates. Further lines of enquiry would 
express these more dynamic substrates (e.g. reduced scFvM or BT6h0) alongside the 
truncated Tat variants and determine if export has been restored. Radioactive labelling 
and pulse-chase analysis of wild-type and truncated TatABC components would also be 
undertaken to identify a connection between stability and turnover of the Tat components 
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While lacking post translational modifications, E. coli encode a multitude of complex 
proteins. Some of these require folding in the cytoplasm, despite the periplasm being their 
site of function. To localise these folded proteins a secondary translocation pathway 
evolved, the Twin-Arginine translocase. The majority of Tat substrates are cofactor-
containing proteins and several studies have shown the Tat system utilises a quality 
control (QC) and proofreading system to ensure only correctly assembled and folded 
proteins are translocated. Several studies have indicated the QC system takes place prior 
to interaction with the Tat machinery, particularly for those substrates that have specific 
chaperones. However, the exact mechanism of this QC process remains unclear. There is 
evidence to support an additional Tat-mediated proofreading mechanism, carried out at 
the translocase itself. The intricacies of how this proofreading mechanism functions are 
not well understood and the information presented in this study aims to give a clearer 
view as to what exactly Tat-mediaWHGSURRIUHDGLQJµVHQVHV¶LQDVXEVWUDWH:HKDYHDOVR
begun attempts to elucidate the domain(s) in the individual Tat components that perform 
the proofreading function. Here in this final chapter the major findings in this study will 
be summarised and future perspectives discussed.  
 
The Tat proofreading mechanism is tolerant of surface charge and hydrophobicity 
but highly dependent on substrate flexibility.   
The first chapter presented in this study identified important factors recognised by the Tat 
SURRIUHDGLQJ PHFKDQLVP DQG JDYH D FOHDUHU YLHZ RI ZKDW H[DFWO\ LV µVHQVHG¶ LQ D
substrate, to more accurately identify what determines whether the substrate is accepted 
or rejected. This was achieved by taking an scFv for which we had structural data and 
generating a range of variants with altered surface charge or hydrophobicity, without 
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altering the folded or structural state of the substrate. None of these variants exhibited 
distinctly reduced export efficiency relative to the unmodified scFv (Figure 14), even 
those with a substantial increase in surface hydrophobicity (Figure 15). This is a perhaps 
surprising phenomenon when taking into consideration other studies which have 
suggested surface hydrophobicity may be a means by which the Tat proofreading system 
rejects substrates for export (Richter et al 2007). Conversely, this study went on to briefly 
assess whether the proofreading system sensed the structural flexibility in a substrate 
through targeting of the scFv with and without prior disulphide formation (Figure 9). 
Interestingly, the more structurally dynamic variant (i.e. without prior disulphide 
formation) was accepted for export ~10-fold less than when the scFv was expressed 
alongside the CyDisCo system and disulphide bonds were formed prior to translocation. 
Moreover, a variant with a highly disordered C-WHUPLQDOµWDLO¶ZDVFRPSOHWHO\EORFNHG
for export (Figure 16).   
These results suggest the Tat proofreading mechanism is geared more towards a sense of 
the structural flexibility of a substrate rather than the surface charge, at least until a 
significant concentration is reached. This is despite evidence in the literature that long, 
unfolded polypeptides can be translocated when given a Tat signal peptide (Cline et al 
2007, Lindenstraub et al 2009, Taubert et al 2014). However, these studies were carried 
out in the garden pea plant (Pisum sativum) thylakoid Tat system. Clustal omega (Goujon 
et al 2010, Sievers et al 2011, MCWilliam et al 2013) alignment of the TatA and TatB 
thylakoidal components of P. sativum, A. thaliana and Z. mays differ greatly from those 
of bacterial Tat systems. The TatA components have a much longer N-terminal domain 
of around 100 residues compared to 12 residues in E. coli with shorter ~20 residue C-
WHUPLQDOµWDLOV¶FRPSDUHGWRUHVLGXHVLQE. coli (Supplementary Figure 2). Moreover, 
a cladogram of the protein sequences indicates E. coli TatA and the thylakoid TatA of P. 
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sativum, A. thaliana and Z. mays share the most distant common ancestor (Supplementary 
Figure 3) and therefore may employ completely different proofreading mechanisms. 
 
Probing the Tat proofreading mechanism with folding variants of a de novo designed 
protein. 
After establishing the Tat proofreading mechanism was more responsive to rejecting a 
substrate based on structural flexibility, we further tested this through the use of a de novo 
designed protein maquette. Here, the sequential inhibition of cofactor binding which was 
linked to a decrease in tertiary structure through 1D NMR, resulted in a decrease in export 
efficiency (Figure 21). With the hemeB-deficient BT6 (BT6h0) almost completely 
blocked in export. A similar scenario to that for the more dynamic scFvM without prior 
disulphide formation and scFvM 26tail with a disordered domain.  
We further went on to show that BT6h0 could be exported when linked behind the export-
compatible BT6h2. This is a perhaps surprising and interesting phenomenon as it implies 
proofreading may take place at a single point ± a checkpoint-like event in the translocation 
process, instead of continuously throughout. This would mean if a substrate was able to 
µ¶SDVV¶¶WKLVFKHFNSRLQWUHJDUGOHVVRILWVIROGHGVWDWHLWLVFRPPLWWHGWRH[SRUW. Such a 
scenario would account for the 10% export efficiency observed in scFvM without its 
disulphide bonds formed and the ability to export the linked BT6 constructs and possibly 
the export of the long, unfolded polypeptides reported by the Cline group.  
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Comparison of periplasmic human Growth Hormone translocated via the Sec or Tat 
system. 
Given the presence of a proofreading mechanism, we thought it pertinent to address the 
folded state of substrates crossing the membrane via the Tat pathway and compare them 
to the same protein reaching the periplasm via the Sec pathway, which transports in an 
unfolded state and lacks a proofreading mechanism. Here it was shown that comparable 
amounts of hGH are present and able to be purified from either pathway. Moreover, this 
protein is folded to the same degree, as evidenced by the comparable 1H NMR spectra 
(Figure 29 and Figure 30).  Thus the Tat system is able to produce a product to at least 
the same quality as those currently available. In light of this it would be interesting to 
conduct a similar comparison with a more complicated or less-stable protein, such as bi-
specifics or certain scFvs or in the presence of the CyDisCo system. 
 
Effect on proofreading for truncation of TatA and TatB. 
To round off this research, we wanted to define the domain responsible for carrying out 
Tat-mediated proofreading. While it was not possible to fully complete this work, the 
groundwork has been laid for attributing a level of functionality to the unstructured tail 
domain of TatA and TatB. We assessed expression via two phenotypic effects ± growth 
on LBA plates supplemented with 2% SDS and formation of cell chains, visible under 
the microscope.  Whilst expression of these TatA and TatB truncation variants was 
confirmed through immunoblotting, the cells demonstrate phenotypes of both the wild-
type and ǻWDW$%&'( strains (Figure 32 and Figure 33). The phenotypic observations may 
be due to a less stable TatA/B/ABC complex or it could be due to impairment of the 
proofreading mechanism.  
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A model for Tat-mediated Quality Control.  
Based on the data presented in this study it is possible to propose a simple mechanism by 
which Tat proofreads substrates. In the translocation process, substrates reach the TatBC 
substrate binding complex before TatA protomers are recruited to facilitate translocation 
(section 1.3.4). Although we were unable to identify whether TatA, TatB or TatAB play 
a role in proofreading and therefore if proofreading takes place before or after TatA 
nucleation, we have shown that a substrate is committed to transport based on its 
structural flexibility (chapter 3 and 4). This is a checkpoint-like event and once passed, 
substrate is committed to export (chapter 4). A summary model of this is shown in Figure 
36.  
This fits in with published data which suggests proofreading takes place only upon initial 
binding of substrate, after which a substrate is committed to export (Cline et al 2007). In 
combination with a mutagenesis study where residues were identified in the disordered 
domains of TatA and TatB and the cytoplasmic loop regions of TatC that possibly 
contributed to proofreading (Rocco et al 2012).  
Combining these data, a more definitive proofreading scenario can be postulated. This 
proceeds as: substrate binds to TatBC and TatA protomers are recruited. At this point the 
structural flexibility of substrate is sensed through transient interactions with the 
disordered domains of TatA and TatB (Taubert et al 2014, Chapter 6) and then substrate 
is either committed to translocation or rejected. Therefore, the export efficiency observed 
for reduced scFvM and BT6h0 is due to those molecules that happen to be in their 
µWLJKWHVW¶FRQIRUPDWLRQXSRQGRFNLQJWR7DW%& A much reduced proportion compared to 
the more structurally stable scFvM produced in an oxidising cytoplasm or BT6 able to 
bind heme.  
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Allowing export of substrates that are slightly flexible ± such as scFvM or hGH lacking 
disulphides (Alanen et al 2015) would make sense from an evolutionary standpoint. For 
example, a recent study has shown that the native Tat substrate CueO, which has copper 
ligands, is translocated in its apo-state. However, CD data of the mature and apo-forms 
were superimposable and indicated no change in structure upon Cu binding (Stolle et al 
2016). Copper ions are toxic to cells as they displace the metal ligands many enzymes 
require to function. Thus it would not be practical to have mature CueO in the cytoplasm 
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Figure 36: Schematic representation for a possible mechanism for Proofreading by 
the TatABC machinery. In the top panel a correctly folded substrate with bound 
cofactor/disulphide formation is assessed by the TatABC proofreading process (possibly 
the C-terminal domains of TatA/TatB), deemed folded and committed to translocation. 
Whereas in the bottom panel a substrate in a structurally dynamic state (e.g. lacking 
FRIDFWRURUQRWWLJKWO\IROGHGHLWKHUKDSSHQVWREHLQLWVµWLJKWHVW¶FRQIRUPDWLRQ
DQGLVFRPPLWWHGWRWUDQVORFDWLRQRULVLQYDULRXVµORRVH¶VWDWHVDQGLVGLUHFWHGWo 
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Future Perspectives.  
The data presented in this study has provided an initial insight into the means by which 
Tat-mediated proofreading broadly determines whether a substrate is accepted or 
rejected for translocation. It has also shown that simple substrates (i.e. hGH) are 
structurally identical in the periplasm when translocated by either the Sec or Tat 
pathway. Whilst the groundwork has been laid to try to identify domains in the Tat 
components that contribute to proofreading, several questions remains unanswered.  
Here we have addressed Tat-mediated quality control and while high-resolution 
structures of the individual TatA and TatBC complexes are coming to light, a greater 
understanding of proofreading will come from structural data of these complexes 
interacting with substrate. These propose a challenge as the Tat components are 
membrane proteins, a notoriously difficult class of proteins to for structural studies. 
Expression of the truncated TatA and TatB components alongside a substrate with 
structural flexibility variants could help determine the domain(s) responsible for Tat-
mediated proofreading. However, care must be taken in this line of study as previous 
reports show overexpression of the Tat components can void the proofreading 
mechanism and expression to this level is a possibility with a plasmid. An issue that 
could be countered by modifying genomic tatABCE.  
A prime approach would be reconstitution of the TatABC system in vitro and the 
subsequent probing with a range of structurally flexible substrates. This would help to 
define Tat-mediated proofreading while eliminating Quality Control contributors and 
other components of a no doubt complicated and intertwined process.  
From a biotechnological viewpoint, the Tat system is at least as good as the Sec system 
and further studies would do well to compare the quality of more complex proteins or 
oligomers.  
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Together these studies would ascertain the domain(s) responsible and the resolution 
of Tat-mediated proofreading. The work presented in this thesis provides a basic 
starting point for these studies and will hopefully provide for a more informed 
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Supplementary Figure 2. Clustal Omega multiple sequence alignment of TatA and 
TatB amino acid sequences from a range of organisms. At ± Agrobacterium tumafaciens. 
Ml ± Mesorhizobium loti. Rs ± Ralstonia salanacearum. Ec ± Escherichia coli. Cr ± 
Chlamydomonas reinhardti. Sc ± Streptomyces coelicar. Hn ± Halobavterium sp. NRC-
1. Ssp ± Synechocystis sp PCC6803. Bs ± Bascillus subtillus. Lm ± Listeria monocytes. 
Dr ± Deinococcus radiodurans. Aa ± Aquifex aeolicus. Maize ± Zea mays. Arabidopsis ± 
Arabidopsis thaliana. Garden Pea ± Pisum sativum. * = fully conserved residue, : = 

























Supplementary Figure 3. Clustal Omega cladogram of TatA and TatB amino acid 
sequences from a range of organisms. At ± Agrobacterium tumafaciens. Ml ± 
Mesorhizobium loti. Rs ± Ralstonia salanacearum. Ec ± Escherichia coli. Cr ± 
Chlamydomonas reinhardti. Sc ± Streptomyces coelicar. Hn ± Halobavterium sp. NRC-
1. Ssp ± Synechocystis sp PCC6803. Bs ± Bascillus subtillus. Lm ± Listeria monocytes. 
Dr ± Deinococcus radiodurans. Aa ± Aquifex aeolicus. Maize ± Zea mays. Arabidopsis ± 
Arabidopsis thaliana. Garden Pea ± Pisum sativum. 
 
 
